19 May 2021  CONFIDENTIAL  Page  1 of 80 STUDY  PROTOCOL  VS-0145 -229 
Protocol  Title:  A Phase  2, Randomized, Open -label,  2-Arm Study  Comparing  
2 Intermittent  Dosing  Schedules  of Duvelisib in Subjects  with Indolent 
Non-Hodgkin Lymphoma  (iNHL)  
Protocol  Number:  VS-0145 -229 
Protocol  Date:  19 May 2021  
Version:  4.0 
Compound:  Duvelisib  
Study  Phase:  Phase  2 
Short Title:  A Phase  2 Study of Intermittent  Dosing  Schedules  of Duvelisib  in Indolent 
Non-Hodgkin Lymphoma  (iNHL)  
Sponsor:  Secura  Bio, Inc. 
[ADDRESS_517860]  
Las Vegas,  NV [ZIP_CODE]  
Tel: (858)  251-1414  
Regulatory  Agency  Identifier  Numbers:  
IND Number:  112,[ADDRESS_517861]  number : 2019 -001381 -14 
Not for Distribution  – Do Not Copy  
This study  protocol  contains  confidential  information  and is the proprietary  property  of 
Secura Bio, Inc. The protocol is for use by [CONTACT_079] [INVESTIGATOR_43865]/her designated 
representatives  participating  in this  investigational  trial. This  protocol  may not  be copi[INVESTIGATOR_410536], Inc.  
NCT #: [STUDY_ID_REMOVED]
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  2 of 80  
 Sponsor  Signatory:  
I have read this  protocol  for Study VS -0145 -229, Version  4.0 and  I approve the design of  this 
study:  
 
Secura  Bio, Inc. 
 
 
 
Medical  Monitor  Contact  [CONTACT_7171]:  
Medical  Monitor  contact  [CONTACT_410571] a study  contact  [CONTACT_4111]. 

Protocol  VS-[ADDRESS_517862]  OF FIGURES  ................................ ................................ ................................ .......................... 6 
1. PROTOCOL  SUMMARY  ................................ ................................ ............................ 7 
1.1. Synopsis  ................................ ................................ ................................ ........................ 7 
1.2. Schema  ................................ ................................ ................................ ........................  10 
1.3. Schedule  of Activities  (SoA)  ................................ ................................ ......................  11 
2. INTRODUCTION ................................ ................................ ................................ ....... 17 
2.1. Study  Rationale  ................................ ................................ ................................ ...........  17 
2.2. Background  ................................ ................................ ................................ .................  17 
2.3. Benefit/Risk  Assessment ................................ ................................ .............................  19 
3. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ............  21 
4. STUDY  DESIGN ................................ ................................ ................................ ........  23 
4.1. Overall  Design  ................................ ................................ ................................ ............  23 
4.2. Scientific  Rationale  for Study Design ................................ ................................ .........  23 
4.3. Justification  for Dose  ................................ ................................ ................................ .. 24 
4.4. End of Study  Definition  ................................ ................................ ..............................  24 
5. STUDY  POPULATION  ................................ ................................ .............................  25 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ........  25 
5.2. Exclusion  Criteria  ................................ ................................ ................................ ....... 25 
5.3. Lifestyle  Considerations  ................................ ................................ .............................  27 
5.4. Definition  of Enrolled  ................................ ................................ ................................ . 27 
5.5. Screen  Failures ................................ ................................ ................................ ............  28 
6. STUDY  INTERVENTION  ................................ ................................ .........................  29 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ............  29 
6.2. Administration  ................................ ................................ ................................ .............  29 
6.3. Preparation/Handling/Storage/Accountability  ................................ .............................  30 
6.4. Measures  to Minimize  Bias:  Randomization  and Blinding  ................................ ........  [ADDRESS_517863]  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ .. [ADDRESS_517864] to Follow -up................................ ................................ ................................ ....... 38 
8. STUDY  ASSESSMENTS  AND PROCEDURES  ................................ .....................  39 
8.1. Efficacy  Assessments  ................................ ................................ ................................ . 39 
8.2. Safety  Assessments  ................................ ................................ ................................ .... 40 
8.3. Adverse  Event  Management  ................................ ................................ ......................  42 
8.4. Quality  of Life Assessments  ................................ ................................ ......................  46 
8.5. Pharmacokinetics  ................................ ................................ ................................ ....... 47 
8.6. Pharmacodynamics  ................................ ................................ ................................ ..... 47 
8.7. Genetics  ................................ ................................ ................................ ......................  47 
8.8. Biomarkers  ................................ ................................ ................................ .................  47 
8.9. Medical Resource  Utilization  and Health  Economics  ................................ ...............  48 
9. STATISTICAL  METHODOLOGY  ................................ ................................ ...........  49 
9.1. Statistical  Hypotheses  ................................ ................................ ................................  49 
9.2. Sample  Size Determination  ................................ ................................ ........................  49 
9.3. Populations  for Analyses  ................................ ................................ ...........................  49 
9.4. Statistical  Analyses  ................................ ................................ ................................ .... 49 
9.5. Interim  Analyses  ................................ ................................ ................................ ........  52 
9.6. Data  Monitoring  Committee  (DMC)  ................................ ................................ .........  52 
10. SUPPORTING DOCUMENTATION AND  OPERATIONAL  
CONSIDERATIONS:  APPENDICES  ................................ ................................ ....... 53 
10.1. Appendix  1: Overview  of Disease  Response  Criteria  ................................ ................  54 
10.2. Appendix  2: CYP3A  Inhibitors,  Inducers,  and Substrates  ................................ .........  58 
10.3. Appendix  3: Clinical Laboratory  Tests  ................................ ................................ ...... 60 
10.4. Appendix  4: Contraception  Guidance  ................................ ................................ ........  62 
10.5. Appendix  5: Eastern  Cooperative  Oncology  Group  (ECOG) Performance  
Status  ................................ ................................ ................................ ..........................  64 
10.6. Appendix  6: Regulatory,  Ethical,  and Study  Oversight Considerations  ....................  65 
10.7. Appendix  7: Abbreviations  ................................ ................................ ........................  69 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  5 of 80  
 10.8. Appendix  8: Protocol  Summary  of Changes  and Version  History  .............................  [ADDRESS_517865]  OF TABLES  
Table 1: Study  Activities  for Duvelisib  Monotherapy  (Cycle  1: 10 Weeks;  Cycles  ≥2: 
4 Weeks)  ................................ ................................ ................................ ....................  11 
Table 2: Pharmacokinetic  and Biomarker  Samplinga,b ................................ ................................ ...........................  16 
Table 3: Objectives  and Endpoints  ................................ ................................ ..........................  21 
Table 4: Study  Intervention  Arms  ................................ ................................ ............................  29 
Table 5: Recommendations  for the Management  of Toxicities  ................................ ...............  32 
Table 6: Prohibited  Concomitant  Therapi[INVESTIGATOR_014]  ................................ ................................ .............  34 
Table 7: Concomitant  Therapi[INVESTIGATOR_014]:  Use with Caution  ................................ ................................  35 
Table 8: Duvelisib  Dosing  Levels  ................................ ................................ ............................  36 
Table 9: CTCAE AE  Grading  ................................ ................................ ................................ .. 44 
Table 10: Biomarker  Samples  and Assessments  ................................ ................................ ........  48 
Table 11: Appendices  ................................ ................................ ................................ .................  53 
Table 12: Revised  Response  Criteria  for Malignant  Lymphoma  (Cheson  2007)  ......................  54 
Table 13: 5-Point  Scale  for Positron  Emission  Tomography  Assessment  (Barrington  
2014)  ................................ ................................ ................................ ..........................  55 
Table 14: Lugano  Response  Criteria  for Malignant  Lymphoma  (Cheson  2014)  .......................  55 
Table 15: Classification  of In  Vivo  Inhibitors  of CYP3A  ................................ .........................  58 
Table 16: Classification  of In Vivo  Inducers  of CYP3A  ................................ ...........................  59 
Table 17: Cytochrome  P450  3A (CYP3A)  Substrates  ................................ ...............................  59 
Table 18: Protocol -required Safety  Laboratory  Assessments  ................................ ....................  60 
Table 19: List of Abbreviations  and Definitions  ................................ ................................ ........  69 
Table 20: Summary  of Changes  for Version  4.0................................ ................................ ........  72 
Table 21: Summary  of Changes  for Version  3.0................................ ................................ ........  73 
Table 22: Primary  Reason  for Each  Version  ................................ ................................ .............  [ADDRESS_517866]  OF FIGURES  
Figure 1: Treatment  Scheme  ................................ ................................ ................................ ..... 10 
Figure 2: Two-stage  Design  for Each  Arm ................................ ................................ ...............  10 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  7 of 80  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis  
Study Title: A Phase  2, randomized, open -label,  2-arm study comparing 2 intermittent dosing 
schedules of duvelisib in subjects with indolent non -Hodgkin lymphoma (iNHL)  
Protocol  Number:  VS-0145 -229 
Phase:  2 
Rationale: Dosing with duvelisib 25 mg twice daily (BID) has  been shown to be efficacious  in 
multiple  Phase  1-3 studies  including  subjects  with iNHL. The efficacy, safety  and tolerability  of this 
dose supported the US approval of duvelisib for the treatment of adult patients  with relapsed or  
refractory (R/R) chronic  lymphocytic  leukemia  (CLL)/ small lymphocytic  lymphoma  (SLL) after at 
least 2 prior therapi[INVESTIGATOR_410537] R/R follicular lymphoma  (FL) 
after at least 2 prior systemic therapi[INVESTIGATOR_014]. The current study will evaluate whether efficacy can be 
achieved and maintained, with acceptable or improved safety and tolerability,  by [CONTACT_410572]  2-week  drug holidays  in 2 different  25 mg BID schedules  in subjects  with R/R iNHL.  
Objectives  and Endpoints  
Objective  Endpoint  
(see Section  9.4 for definitions)  
Primary  
Evaluate  the efficacy  of duvelisib  administered 
with prescribed drug holidays in subjects with 
iNHL  Overall Response Rate (ORR) according to the 
2007 revised International Working Group (IWG) 
Criteria ( Cheson 2007 ) 
Secondary  
Evaluate supportive efficacy measures of 
duvelisib  administered  with prescribed  drug 
holidays in subjects with iNHL  • ORR according  to 2014  Lugano  criteria 
(Cheson  2014 ) 
Note: all additional secondary response 
endpoints  as well as progression -free survival 
(PFS), will  be assessed  separately using  2007 
revised IWG  criteria  (Cheson  2007 ) and 2014 
Lugano criteria ( Cheson 2014 ) 
• ORR, at 6, 12, 18, and  [ADDRESS_517867] 
dose of study intervention  
• Progression -free Survival  
• Time  to Treatment  Failure  (TTF)  
• Duration  of Response  (DOR)  
• Overall  Survival  (OS) 
• Lymph  Node  Response  Rate (LNRR)  
• Time  to the First Response  (TTFR)  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  8 of 80  
  
Evaluate  the safety  and tolerability  of duvelisib 
administered with prescribed drug holidays in 
subjects with iNHL  Adverse  events (AEs), serious  AEs (SAEs), vital 
signs, physical examinations, and clinical 
laboratory  values  
Characterize the pharmacokinetics (PK) of 
duvelisib and metabolite  IPI-656 when duvelisib 
is administered with prescribed drug holidays  in 
subjects with iNHL  PK parameters  for duvelisib  and metabolite 
IPI-656 
Exploratory  
Evaluate Quality of Life (QoL) in subjects with 
iNHL treated  with duvelisib  with prescribed  drug 
holidays  • Eastern  Cooperative  Oncology  Group  (ECOG) 
Performance  Score  
• EQ-5D-3L questionnaire  responses  
Evaluate  potential biomarkers  of clinical efficacy 
and/or safety of duvelisib administered with 
prescribed drug holidays in subjects with iNHL  • Blood assessments  of immune cell 
populations, chemokines, cytokines, 
phosphorylated  proteins, and/or circulating 
tumor ctDNA  
• Fecal  assessments  of protein,  DNA,  and or 
RNA  
• Tumor biopsy evaluation of biomarkers such 
as gene and copy number variation, RNA 
expression, protein  expression, and/or  immune 
cell content  
Overall  Design:  
This is  a Phase 2, randomized, open -label, 2 -arm study designed to evaluate the efficacy and safety of 
prescribed  drug holidays  of duvelisib  treatment  in subjects  with R/R iNHL  who have received  at least 1 
prior systemic therapy.  
Subjects  will be stratified by [CONTACT_365357][INVESTIGATOR_014]  (1 or > 1), bulky disease status  (longest 
diameter of baseline  lesion < 5 cm or ≥ 5 cm) and time  since last recurrence  (≥ 24 months  or < 24 
months). Subjects  will be  randomized  to Arm 1  or Arm 2  in a 1:1 fashion. Each  treatment arm will be 
analyzed  separately.  
The study is a 2 -stage design. For each arm : in the first stage, approximately 15 subjects  will be 
enrolled. Responses  will be assessed  by [CONTACT_410573] 2007 revised IWG criteria 
(Cheson  2007 ) (primary  endpoint) and  2014  Lugano  criteria  (Cheson  2014 ). The evaluation  of the  first 
stage will take place after the [ADDRESS_517868] been followed for a minimum of 3 cycles. If 
there are fewer  than 6 responders  (partial  response [PR]  or complete response [CR])  among the first 
15 subjects in each arm, consideration may be given to stoppi[INVESTIGATOR_410538]. Otherwise, 36 additional 
subjects will be enrolled for a total of 51 per arm. Enrollment will  be continuous  between Stage 1 and 
Stage  2. 
Number  of Subjects:  
Approximately 102 subjects  will be  enrolled and randomized at multiple  sites globally. The  study will 
employ  a 2-stage  approach  with a planned  enrollment of approximately  30 subjects  for Stage  1 and up 
to approximately 72 additional subjects for Stage 2.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  9 of 80  
  
Intervention  Groups  and Duration:  
• Arm 1: duvelisib  25 mg BID for one  10-week  cycle  followed  by 25 mg BID in Weeks 3  and 4 of 
each subsequent 4 -week cycles until disease progression, unacceptable toxicity, or withdrawal.  
• Arm 2: duvelisib  [ADDRESS_517869] continuing to receive benefit will be provided the opportunity to 
continue  to receive  duvelisib. Long -term continued  treatment may  be provided  via an expanded  access 
program consistent with local regulations, such as the Secura Bio NPP.  
Data  Monitoring  Committee:  None.  
Disclosure  Statement:  This is a parallel -group  unblinded  treatment  study  with 2 arms.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  10 of 80  
 
1.2. Schema  
Figure  1: Treatment  Scheme  
 
Abbrevia  tions:  BID:  twice  daily.  
 
Solid  sections:  duvelisib  25 mg BID;  hashed  sections:  drug holiday.  Subjects  will be randomized  1:1 to Arms  1 and 
2. Subjects  will be assessed  for disease  response  after approximately  10 weeks  (i.e., within  7 days of the start of 
Cycle  2) and then within  7 days of the start of Cycles  4, 6, 9, 13, 17, and every  4th cycle  thereafter  until disea  se 
progression,  unacceptable  toxicity  or withdrawal.  (*): a ssessment  of ORR  a fter a minimum  of [ADDRESS_517870]-sta ge subjects  (see Figure  2) to determine  Stage  2 enrollment.  
 
 
Figure  2: Two -stage  Design  for Each  Arm  
 
Abbrevia  tions:  CR: complete  response;  N: number  of subjects;  PR: partial  response;  ORR:  overall  response  rate. 
The decision  to proceed  to Stage  2 will be supported  by [CONTACT_410574],  including  types  of responses, 
safety  data,  and discontinuation  rates.  A trea tment  arm may also not proceed  to the second  stage  if the totality  of the 
data is compelling  (e.g.,  accumulating  enough  data in  Stage  1 to conclude  the ORR  exceeds  30%).  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  11 of 80  
 1.3. Schedule  of Activities  (SoA)  
Table  1: Study  Activities  for Duvelisib  Monotherapy  (Cycle  1: 10 Weeks;  Cycles  ≥2: 4 Weeks)  
 
 
 
 
 
Activity   
Screening 
D-30 to 
D-1 Cycle  1  
Cycle  2 Cycle 
3+  
 
 
EoTa Safety 
F/Ub 
30d (+7) 
postdose    
 
 
 
Notes   
D1 D14 
(-3) D29 
(+3) D43 
(±3) D57 
(±3) D1 
(±3 D14 
(-3) D1 
(±3) 
 
 
Informed  Consent   
 
X            Potentially eligible subjects must  sign an ICF prior 
to initiating any study specific procedures.  
Standard of care assessments that fulfill study 
eligibility  requirements may  be performed  prior  to 
subject  signing  the ICF. 
Inclusion/Exclusion 
Criteria  X             
 
Randomization  X 
(D -7 
to -1)            Subject  must  sign informed  consent,  meet 
inclusion/exclusion  criteria, and complete all other  
screening  activities prior to randomization.  
Medical  History, 
Demographics   
X            Medical History includes histologic  lymphoma 
diagnostic and prior treatment and response  
information,  FLIPI -1 score  
 
Archival  Tumor  Tissue   
X            Tumor  tissue  is not required  for enrollment,  but 
should be submitted from all enrolled subjects, if 
available.  Sample should be  FFPE  tissue  and will 
be used to evaluate prognostic biomarkers.  
 
Tumor  Biopsy 
(optional)   
 
X            If a transformation to a  more  aggressive  subtype  of 
lymphoma is suspected, a biopsy  may be  
performed  at Investigator’s  discretion.  
If this sample  is collected, please  see Archival 
Tumor Tissue instructions  above.  
Full Physical 
Examination  X X           If performed  within  7 days of  C1D1,  then 
screening  results can be used for C1D1.  
Focused  Physical 
Examination     
X  
X  
X  
X  
X  
X  
X  
X   Disease -focused assessments including  liver/spleen  
size, clinical assessment of tumor masses,  and B  
symptoms.  
Vital  Signs  X X X X X X X X X X   Vital signs measured in a semi -supi[INVESTIGATOR_410539] [ADDRESS_517871].  
Computed  
Tomography  (CT) X   
X   All subjects require CT or FDG -PET -CT scans. 
MRI may  be used  instead  of CT scans if  CT cannot  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  12 of 80  
  
 
 
 
 
Activity   
Screening 
D-30 to 
D-1 Cycle  1  
Cycle  2 Cycle 
3+  
 
 
EoTa Safety 
F/Ub 
30d (+7) 
postdose    
 
 
 
Notes   
D1 D14 
(-3) D29 
(+3) D43 
(±3) D57 
(±3) D1 
(±3 D14 
(-3) D1 
(±3) 
Scans of the Chest, 
Abdomen  and Pelvis     
 
Day 1 of Cycles  2, 4, 6, 9, 13,  17, and Every  4th 
Cycle Thereafter  
(Window:  Day -7 to Day 1 of Each  Cycle)     be done,  but the same  method  must  be used 
throughout  the study.  A scan will be  performed at 
the EoT if one  was not performed within 30 days 
of the EoT Visit.  
 
Response  Assessment     
X   Response  will be assessed  separately  using  2007  
revised IWG criteria  (Cheson 2007 ) and 2014 
Lugano criteria ( Cheson 2014 ) 
 
 
 
Bone Marrow  Aspi[INVESTIGATOR_27505]/or  Biopsy     
 
 
 
As necessary  to confirm  CR If a bone  marrow/aspi[INVESTIGATOR_410540]  
[ADDRESS_517872] of  care, 
the pathology report will be provided to the  
Sponsor. If a radiologic CR  according  to 2007 
revised IWG criteria  (Cheson 2007 ) is observed  
during  the course  of the  study, then a bone  marrow 
biopsy should be done to confirm CR. The  
pathology  report  will be provided  to the Sponsor.  
 
 
ECG  (12-lead)   
 
X            QTc measurements (as measured by [CONTACT_410575]) will use the Fridericia’s correction 
method. Additional on -treatment or follow -up 
ECGs  may be performed at the Investigator’s 
discretion as clinically indicated.  
ECHO/ 
MUGA   
X            ECHO  or MUGA  scan.  Additional  on-treatment  or 
follow -up echocardiograms may be performed  at 
the Investigator’s discretion as clinically indicated.  
Concomitant 
Medications  and 
Procedures   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X   
AE/SAE  Assessment  X X X X X X X X X X X   
Coagulation  tests X            Prothrombin time, partial thromboplastin time and  
international  normalized ratio  
 
 
Viral  screening   
 
X            Hepatitis serology: HCV  Ab, HBsAg, HBcAb. 
CMV/EBV  serology or  viral  load.  HIV test  is not 
required  if a prior  negative  test within  9 months is 
available.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  13 of 80  
  
 
 
 
 
Activity   
Screening 
D-30 to 
D-1 Cycle  1  
Cycle  2 Cycle 
3+  
 
 
EoTa Safety 
F/Ub 
30d (+7) 
postdose    
 
 
 
Notes   
D1 D14 
(-3) D29 
(+3) D43 
(±3) D57 
(±3) D1 
(±3 D14 
(-3) D1 
(±3) 
CMV  Reactivation 
Monitoring    Subjects  with a history  of CMV  infection/reactivation  or viremia  
should be  monitored for  reactivation by [CONTACT_410576]    
C-Reactive  Protein  X  
Obtain  when  Grade  ≥ [ADDRESS_517873] results can be  used for 
C1D1 if tests are performed within 7 days of 
C1D1.  
Immunoglobulin  blood 
levels   
X    
X    
X  X 
(even  # 
cycles)      
IgA,  IgG, IgM 
 
 
Hematology   
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X   
 
X  
 
X   Hematology  panel  plus a 5-part differential.  
Testing must be conducted, and results available, 
within  [ADDRESS_517874]  be 
conducted,  and results  available,  within  7 days 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  14 of 80  
  
 
 
 
 
Activity   
Screening 
D-30 to 
D-1 Cycle  1  
Cycle  2 Cycle 
3+  
 
 
EoTa Safety 
F/Ub 
30d (+7) 
postdose    
 
 
 
Notes   
D1 D14 
(-3) D29 
(+3) D43 
(±3) D57 
(±3) D1 
(±3 D14 
(-3) D1 
(±3) 
             prior to administration of first dose of duvelisib. 
Screening  test results can  be used  for C1D1  if tests 
are performed within 7 days of C1D1.  
 
ECOG  Performance 
Status   
X  
X  
 
X   
 
X  
 
X  
X   If the ECOG Performance Status assessed at 
Screening is performed within 7 days of  C1D1,  the 
Screening assessment can be used and does not  
need  to be repeated  at C1D1  (predose).  
EQ-5D-3L 
Questionnaire  X X  
X   
X  
X X   Administered predose  and prior  to other  procedures 
during  treatment  visits  
 
Pharmacokinetic  and 
Biomarker  
Assessments    
X  
X  
X   
X  
X  
X X 
see 
note    For Cycles  ≥ 3, obtain stool  sample  if subject  has 
Grade ≥ [ADDRESS_517875]  
representative  fragment  of tissue  and/or  
representative section of paraffin block from 
biopsy  if taken  for colitis or  Grade  ≥ [ADDRESS_517876] year on treatment  only 
Duvelisib 
Administration  
(Please see required 
and recommended 
prophylaxis in 
Section 6.6.1)   
X 
(C1D14  
AM dose  in 
clinic)   
 
 
X  
 
 
X  
 
 
X  
 
 
X  
 
 
X  
 
 
X     
Administration of the first dose should be 
scheduled to occur within 1 week  after  
randomization. See  Section 6.1 for dosing 
schedule.  
Abbreviations:  AE/SAE: adverse event/serious  adverse  event;  ALP: a  lkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
BID:  twice  da ily; CxDx:  Cycle  x, Day x; CMV:  cytomegalovirus;  CR: complete  response;  CT: computed  tomography;  EBV:  Epstein -Barr virus;  ECG: 
electrocardiogram;  ECOG:  Eastern  Cooperative  Oncology  Group;  ECHO:  echocardiogram;  EoT:  end of treatment;  FDG -PET:  18fluoro -2-deoxy -d-glucose - 
positron  emission  tomography;  FFPE:  formalin -fixed  paraffin -embedded  ; FLIPI -1: Follicula  r Lymphoma  International  Prognostic  Index;  F/U: follow -up; 
HBcAb:  hepatitis  B core antibody;  HBsAg:  hepatitis  B surface  antigen;  HCVAb:  hepatitis  C antibody;  hCG:  human  chorionic  gonadotropin;  HIV:  human  
immunodeficiency  virus;  HLA:  human  leukocyte  antigen;  ICF: informed  consent  form;  iNHL:  indolent  non-Hodgkin  lymphoma;  IWG:  international  working 
group;  LDH:  lactate  dehydrogenase;  MRI:  magnetic  resonance  imaging;  MUGA: multi -gated  acquisition;  PCR:  polymerase  chain  reaction;  WCBP:  women  of 
childbearing  potential.  
Protocol  VS-[ADDRESS_517877] scan.  
b. Sa fety follow -up visit to be performed  30 + [ADDRESS_517878]  does not require  laboratory  and/or  other  procedures  related  to any new or ongoing  AEs,  in 
which case  a clinical  visit will be  required.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  16 of 80  
 Table  2: Pharmacokinetic  and Biomarker  Samplinga,b 
 
 
 
Cycle   
Study 
Day  
 
Time  Points  Whole 
blood 
for PKc Whole  blood  for 
pharmacodynamic 
biomarkers  
(U.S.  sites only)  Serum  and 
plasma  for 
biomarkers  Whole  blood 
for immune 
cell analysis  Stool  sample 
for biomarker 
analysis  
1 1 Predose  X X X X Xe 
1 hour (± 5 min)  postdose  X X    
2 hours  (± 10 min)  postdose  X X    
4 hours  (± 10 min)  postdose  X     
14 (-3)d Predose  X X    
1 hour (± 5 min)  postdose  X     
2 hours  (± 10 min)  postdose  X     
4 hours  (± 10 min)  postdose  X     
29 (+3)d Predose  X     
1 hour (± 5 min)  postdose  X     
2 hours  (± 10 min)  postdose  X     
4 hours  (± 10 min)  postdose  X     
57 (±3)d Predose    X X  
2 1 (±3) Anytime  during  visit   X X Xe 
14 (-3) Anytime  during  visit   X X  
3+ Any Anytime  during  visit     Xe 
Abbreviations:  CR: complete  response;  CxDx:  Cycle  x Day x; PK: pharmacokinetics  
a. Any changes  to this sampling  plan (e.g.,  reductions  in the number  of sample  collections)  will be provided  in the study  lab manual.  
b. In addition  to the samples  shown  in this table,  provide  (if feasible)  a sample  of any  colon  biopsies  taken  for colitis  or Grade  ≥ [ADDRESS_517879]  occur  on a dosing  day. After  a subjecthas  had a dose reduction  and received  ≥ 10 consecutive  days of the reduced  dose (not including 
scheduled  dose holidays),  PK sa mpling  as shown  for C1D1  will be repea  ted. 
d. On C1D14,  C1D29  and C1D57,  the morning  dose of study  medication  will be administered  in the clinic  to accommodate  PK a nd/or  biomarker  sampling.  
e. The C1D1  stool  sample  may be collected  up to 7 days prior  to C1D1.  C2D1  stool  samples  may be collected  up to 3 days prior  to these  visits.  Stool  samples 
may  be collected  either  predoseor  postdose.  Obtain  additional  stool  sample  if subjecthas  colitis  or Grade  ≥ 3 diarrhea.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  17 of 80  
  
2. INTRODUCTION  
Duvelisib  (VS-0145)  is a synthetic  orally -active  small  molecule  dual inhibitor  of 
phosphoinositide 3 -kinase (PI3K) -δ and PI3K -γ that is being  developed  by [CONTACT_46579], Inc. 
(Secura Bio;  study Sponsor)  for the treatment  of follicular  lymphoma (FL)  and other  indolent  
non-Hodgkin lymphomas (iNHLs), T -cell lymphoma and other  hematological  malignancies, and 
solid tumor malignancies.  
2.1. Study  Rationale  
The registrational  studies  for duvelisib 25  mg twice daily (BID)  in chronic lymphocytic leukemia 
(CLL)/small lymphocytic lymphoma (SLL; the DUO study) and for iNHL, including  FL (the 
DYNAMO study), were positive with respect to their primary endpoints of progression -free 
survival (PFS; DUO) and overall response rate (ORR; DYNAMO) and included subjects  who 
received at  least 1 prior  treatment  regimen. Ultimately duvelisib  (COPI[INVESTIGATOR_410541]®) 25 mg  BID was 
approved by [CONTACT_168719] (US) Food and Drug  Administration (FDA) for the treatment of 
adult patients with relapsed or refractory (R/R) FL and SLL after ≥ [ADDRESS_517880]  in the setting  of ≥ 2 prior  systemic therapi[INVESTIGATOR_014], which 
supported the approval  in this  specific subset  of subjects. Although several  other  regimens  (e.g., 
autologous transplantation for younger patients, repetition of the first -line treatment,  
bendamustine plus obinutuzumab or rituximab) are currently recommended by [CONTACT_410577] (ESMO)  and National  Comprehensive Cancer  Network (NCCN)  
guidelines in the second -line setting, relapses are common, and  the unmet  medical  need remains 
high in this patient population ( ESMO 2019 , NCCN 2019 ). 
The post -hoc analysis of the DUO study showed  that response to duvelisib was improved  or 
maintained in most  subjects who had  ≥ 1 dose interruption  (DI) for > 1 week (84%)  or > 2 weeks 
(82%), then followed by ≥ 3 weeks on duvelisib.  PFS was also similar between subjects with  
≥ 1 DI and those without  DI for >  1 week or >  [ADDRESS_517881]  3 months of therapy 
(median PFS: > 1 week, 17.8 vs  16.3 months;  > 2 weeks, 17.8  vs 16.3 months)  (Flinn 2019 ). 
These data support the hypothesis that prespecified [ADDRESS_517882] efficacy.  
This study (VS -0145 -229) is a proof -of-concept  study  that will evaluate whether  duvelisib 25 mg 
BID efficacy can be achieved  and maintained, with acceptable  or improved safety and  
tolerability, by [CONTACT_410578]  2-week  drug holidays in 2 different  schedules in 
subjects with R/R iNHL after failure of at least 1 line of prior therapy.  
2.2. Background  
2.2.1. Non-Hodgkin  Lymphoma  
Non-Hodgkin lymphoma  (NHL) is one of  the most common  malignancies  in the US, Europe, 
and Asia.  It is expected that  about  74,200 people  will be diagnosed with NHL  in the US  in 2019 
with about 19,970 projected  deaths  from  this disease ( NCI-SEER 2019 ). Indolent NHL (iNHL) 
accounts for approximately one third of all NHL cases. Follicular lymphoma  (FL) is the most  
common  iNHL  type,  followed  by [CONTACT_106618],  and marginal  zone  B-cell lymphoma  (MZL,  that includes  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  18 of 80  
 nodal  and splenic marginal  zone), which  occur  in approximately 30%, 7%, and  4% of  all NHL 
cases, respectively ( Swerdlow 2016 ). 
The course of iNHL  is variable. While some patients  can remain asymptomatic for  extended 
periods, others may require immediate intervention. Rituximab -based  regimens are common 
front -line treatment choices in patients with FL and MZL, and ibrutinib or venetoclax in  
combination  with obinutuzumab are  preferred  choices  in patients  with SLL (NCCN  2019 ). 
Although  most  patients  with iNHL  have  durable  responses  to initial  treatment  with prolonged  
remission, relapses, requiring  serial  retreatment, are common. Almost  all patients will  eventually 
progress or have a disease recurrence,  and advanced -stage iNHL remains incurable ( Cheson  
1998 , Hitz 2011 , Sehn 2016 ). Recent  data show  that patients  with FL  who progress  within 
[ADDRESS_517883] a lower 5 -year overall  survival  (OS) rate (50%) than  
patients without  early progression (90%)  after front -line combination  therapy  with rituximab 
plus cyclophosphamide, doxorubicin, and prednisone (R -CHOP) ( Casulo 2015 ). 
Despi[INVESTIGATOR_410542], major  challenges  remain, 
which include cumulative toxicities from multiple  therapi[INVESTIGATOR_410543] -grade lymphomas ( Coutre 2015 , Federico  2000 ). While allogeneic stem cell 
transplantation could  be potentially curative, only  a small  number of patients are eligible for this 
therapy, and there is unmet medical need for new therapi[INVESTIGATOR_014].  
2.2.2. PI3 Kinases  
PI3Ks catalyze the production of phosphatidylinositol (3, 4, 5) -trisphosphate, leading to 
activation of downstream  effector pathways important for cellular survival, differentiation,  and 
function. There  are 4 mammalian  isoforms of  class 1 PI3Ks:  PI3K -α, β, δ  (class 1a), and PI3K -γ 
(class 1b) ( Fruman 2017 ). 
PI3K -α and PI3K -β are widely  expressed  and are important  mediators  of signaling  from  cell 
surface receptors, while the PI3K -δ and PI3K -γ isoforms are more narrowly expressed in 
hematopoietic lineage cells, immune cells, and malignant hematopoietic cells. Pathways 
mediated by [CONTACT_976]3K -δ and PI3K -γ are involved in diverse  processes  of cell growth, survival,  
proliferation, migration, differentiation, and  metabolism. Since central  regulatory roles for either 
or both enzymes have  been  demonstrated in B  cells, T  cells, macrophages/monocytes, mast  cells, 
and natural killer (NK) cells, both PI3K -δ and PI3K -γ are believed to be important for the  
development  and persistence  of autoimmune  disease  and hematologic malignancies ( Curran  
2014 , Ortiz -Maldonado 2015 , Steele 2014 , Westin 2014 ). 
PI3K -δ, and PI3K -γ activity  supports  the growth  and maintenance  of cancer  cells and the 
supportive tumor  microenvironment. Data from  nonclinical  in vitro and in vivo studies  show  that 
inhibition of PI3K -δ, and PI3K -γ results  in significant  efficacy against  hematologic malignancies 
and solid tumors. Duvelisib is being  developed  due to its ability to inhibit PI3K -δ and PI3K -γ 
and reduce their  cancer -promoting  effects.  The direct  effect  of duvelisib on primary  malignant 
hematologic tumor cells was demonstrated by [CONTACT_410579] -mediated  growth inhibition  of both 
primary CLL  cells and cell  lines derived from  transformed FL, diffuse large B -cell lymphoma 
(DLBCL), mantle cell lymphoma (MCL), multiple myeloma, and  T-cell lymphoma/leukemia 
(Dong 2014 , Faia 2015 ). 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  19 of 80  
 2.2.3. Duvelisib  in Hematologic  Malignancies  
Duvelisib has shown clinical activity in various hematologic malignancies,  including CLL, 
iNHL, and cutaneous and  peripheral  T-cell lymphoma  (CTCL  and PTCL, respectively). In the 
Phase 1 study in hematologic malignancies,  including iNHL ( Flinn 2018 ), the recommended 
Phase 2 dose (RP2D) was determined to be 25 mg  BID with maculopapular rash, alanine 
aminotransferase/aspartate aminotransferase (ALT/AST) elevation, neutropenia,  and cellulitis 
observed as dose -limiting toxicities.  
As of [ADDRESS_517884]  been exposed  to duvelisib as monotherapy 
or in combination with another agent, including  approximately 814 subjects with hematologic 
malignancies in Company - or Investigator -sponsored  studies.  Indications include NHL subtypes 
of mature B -cell lymphomas (e.g., FL, CLL/SLL, DLBCL, marginal  zone lymphoma,  MCL)  and 
mature T -cell lymphomas (e.g., PTCL, CTCL), acute myeloid leukemia, and  multiple myeloma. 
Studies have been conducted globally in countries including  the US, Canada,  the United  
Kingdom, Austria, [LOCATION_009], [LOCATION_013], Georgia, Hungary,  Italy, Spain, Belarus,  Belgium, 
Bulgaria, Czech Republic, and Australia.  
Duvelisib was approved by [CONTACT_109344] 2018 for the treatment  of patients with R/R 
CLL/SLL  after at least 2 prior therapi[INVESTIGATOR_410544] R/R FL after at 
least 2 prior systemic therapi[INVESTIGATOR_014] ( COPI[INVESTIGATOR_410541] 2018 ). Please see the Duvelisib Investigator’s 
Brochure (IB) for detailed descriptions of nonclinical and clinical safety and efficacy results. 
These  data,  together  with the  available  safety  data,  support  the ongoing  evaluation of  duvelisib in 
subjects with hematologic malignancies.  
2.3. Benefit/Risk Assessment  
2.3.1. Risk  Assessment  
As of 19 July 2018, in 588 subjects treated  with duvelisib  monotherapy  in hematologic 
malignancy studies (see Section [IP_ADDRESS].2  in the IB), the most  frequent  treatment -emergent  
adverse events (TEAEs)  (≥ 20% of subjects)  reported  were diarrhea/colitis (49.0%), neutropenia 
(34.7%), rash (34.7%),  fatigue (33.2%), pyrexia (30.3%), cough (26.7%), nausea  (26.0%),  
transaminase elevation (22.8%), musculoskeletal pain (22.6%), anemia (22.4%), upper 
respi[INVESTIGATOR_1092] (22.3%), and pneumonia (21.6%). The most frequently reported 
TEAEs, diarrhea and neutropenia,  are amenable to early recognition and  intervention.  These 
events infrequently resulted in treatment discontinuation with management, including dose 
modifications  and supportive care.  Many of the more severe TEAEs, such as infections and 
hematologic abnormalities, are commonly observed in subjects with advanced B -cell 
malignancies.  Adverse  events  (AEs)  of special  interest  (AESIs),  such as diarrhea,  colitis,  
pneumonitis, rash,  and transaminase elevations, have  been  well-described  with the use of PI3K -δ 
inhibitors and immuno -oncology therapi[INVESTIGATOR_014]. The most commonly occurring AEs infrequently 
resulted in treatment discontinuation,  representing  a manageable safety profile in subjects with  
advanced  hematologic  malignancies.  
The identified risks  for duvelisib treatment  are infections, diarrhea/colitis, cutaneous  reactions, 
pneumonitis, transaminase elevations,  and neutropenia. Potential risks are hepatotoxicity and 
reproductive toxicity. Guidance  on management of these  AEs, including duvelisib dose  
interruptions  and modifications,  is provided  in Section  6.6 and Section  6.7. Detailed  information  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  20 of 80  
 about  the known and  expected  risks  and reasonably expected AEs of duvelisib may be found in 
the IB.  
2.3.2. Benefit  Assessment  
Subjects  may derive benefit  due to improvements  in symptoms  and tumor  control. Duvelisib 
treatment produced clinical activity in subjects with hematologic malignancies,  including 
CLL/SLL,  FL, and PTCL. In the pi[INVESTIGATOR_410545]/SLL study (Study IPI -145-07), duvelisib  
monotherapy  resulted  in statistically  significant  improvement  in PFS (16.4  months vs  9.1 
months)  and ORR  (78% vs 39%)  compared to ofatumumab in subjects who had  received at  least 
[ADDRESS_517885] 
subjects  treated with duvelisib (85%), representing  a statistically significant  treatment  effect  over 
ofatumumab (16%). In subjects with FL  in a Phase 2 study in iNHL (IPI -145-06), the ORR was 
42.2%, meeting  the primary endpoint (p <  0.[ADDRESS_517886] the null hypothesis that ORR was ≤  
30% per Independent Review Committee [IRC]). In subjects with PTCL in a Phase 1 dose 
escalation study (IPI -145-02), the observed ORR  was 53.3%.  More detailed information  about 
the clinical efficacy  observed  in duvelisib studies can  be found in the IB.  
2.3.3. Overall  Benefit:  Risk  Conclusion  
Clinical study results to date support a favorable  benefit -risk of duvelisib for subjects with 
hematologic malignancies. Efficacy has been seen in multiple studies, including significant 
improvements in ORR and PFS  relative to the comparator in a pi[INVESTIGATOR_410546] R/R CLL/SLL 
(Study IPI -145-07) and positive  ORR and duration of response  (DOR) in a single -arm FL study 
(Study IPI -145-06). Important identified risks include infections, diarrhea/colitis, cutaneous 
reactions, pneumonitis, neutropenia, and  ALT/AST  elevations. The efficacy  and safety profile of 
duvelisib,  as detailed in the  IB, indicates  that the benefits  of duvelisib therapy outweigh the  risks. 
In addition, the alternative dosing schedules being  evaluated  in the current study  may improve  
the safety profile while maintaining  the efficacy benefit, potentially increasing the benefit:risk  
for subjects in  this study.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  21 of 80  
  
3. OBJECTIVES  AND  ENDPOINTS  
Table  3: Objectives  and Endpoints  
 
Objective  Endpoint  
(see Section  9.4 for definitions)  
Primary  
Evaluate  the efficacy  of duvelisib  administered 
with prescribed drug holidays in subjects with 
iNHL  Overall Response Rate (ORR) according to the 
2007 revised International Working Group (IWG) 
Criteria ( Cheson 2007 ) 
Secondary  
Evaluate supportive efficacy measures of 
duvelisib  administered  with prescribed  drug 
holidays in subjects with iNHL  • ORR according  to 2014  Lugano  criteria 
(Cheson  2014 ) 
Note: all additional secondary response 
endpoints,  as well as progression -free survival 
(PFS), will be  assessed separately using 2007 
revised IWG  criteria  (Cheson  2007 ) and  2014 
Lugano criteria ( Cheson 2014 ) 
• ORR, at 6, 12, 18, and  [ADDRESS_517887] 
dose of study intervention  
• Progression -free Survival  
• Time  to Treatment  Failure  (TTF)  
• Duration  of Response  (DOR)  
• Overall  Survival  (OS) 
• Lymph  Node  Response  Rate (LNRR)  
• Time  to the First Response  (TTFR)  
Evaluate  the safety  and tolerability  of duvelisib 
administered with prescribed drug holidays in 
subjects with iNHL  Adverse  events (AEs), serious  AEs (SAEs), vital 
signs, physical examinations, and abnormal 
laboratory  values  
Characterize the pharmacokinetics (PK) of 
duvelisib and metabolite  IPI-656 when duvelisib 
is administered with prescribed drug holidays  in 
subjects with iNHL  PK parameters  for duvelisib  and metabolite  IPI- 
656 
Exploratory  
Evaluate  Quality  of Life  (QoL) in  subjects  treated 
with duvelisib with prescribed drug holidays  • ECOG  Performance  Score  
• EQ-5D-3L questionnaire  responses  
Evaluate  potential biomarkers  of clinical efficacy 
and/or safety of duvelisib administered with 
prescribed drug holidays in subjects with iNHL  • Blood assessments  of immune cell 
populations, chemokines, cytokines, proteins 
and/or circulating tumor (ctDNA)  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  22 of 80  
  
 • Assessments  of protein,  DNA,  and or RNA  in 
fecal microbiota  
• Tumor biopsy evaluation of biomarkers such 
as gene and copy number variation, RNA 
expression, protein  expression, and/or  immune 
cell content  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  23 of 80  
 4. STUDY  DESIGN  
4.1. Overall  Design  
This is a Phase  2, randomized,  open -label,  2-arm study designed to evaluate  the efficacy and 
safety of alternative dosing  schedules of  duvelisib treatment  in subjects with R/R  iNHL  who 
have received at least 1 prior systemic therapy. This is a multi -site global study.  
Subjects  will be stratified by [CONTACT_410580][INVESTIGATOR_014]  (1 or  > 1), bulky disease status  (longest 
diameter of  baseline lesion  < 5 cm or ≥ 5 cm) and time since last recurrence (≥  24 months or  
< 24 months).  
Subjects  will be randomized  to Arm  1 or Arm 2 in a  1:1 fashion.  
• Arm 1: duvelisib 25 mg  BID for one 10 -week cycle  followed  by 25 mg  BID on 
Weeks 3 and 4 of each subsequent 4 -week  cycles until disease progression, 
unacceptable toxicity, or withdrawal.  
• Arm 2: duvelisib 25 mg  BID on Weeks  1, 2, 5, 6, 9 and 10 of one  10-week cycle,  then 
on Weeks 3 and 4 of each subsequent 4 -week  cycles  until disease progression, 
unacceptable toxicity, or withdrawal.  
The study has  a 2-stage  design (see  Figure  2). For each arm:  in the  first stage,  15 subjects  will be 
enrolled. Responses will be assessed by  [CONTACT_410581] 2007 revised IWG 
criteria ( Cheson 2007 ) (primary  endpoint) and the 2014 Lugano  criteria ( Cheson  2014 ). The  
evaluation of the first stage will take place after the enrolled subjects have been followed for a 
minimum of 3 cycles. If there  are fewer than 6 responders (partial response [PR] or complete 
response [CR])  among  the first  15 subjects per  arm, consideration may  be given to stoppi[INVESTIGATOR_410547]. Otherwise, approximately 36  additional  subjects will  be enrolled for a total  of 51 per arm. 
Enrollment  will be continuous between Stage 1 and Stage 2. If fewer  than 22 (43%)  responders 
(PR or CR) are observed in [ADDRESS_517888] is randomized.  
4.2. Scientific  Rationale  for Study  Design  
Dosing  with duvelisib 25 mg  BID has been shown  to be efficacious  in multiple Phase 1 -3 studies 
including  subjects  with iNHL.  Data from the pi[INVESTIGATOR_53881] 3 CLL/SLL  study (DUO)  and Phase 2 
FL study (DYNAMO) showed that most tumor responses  occurred by  [CONTACT_42334] [ADDRESS_517889] subjects who had  ≥ 1 DI for >  1 week (84%) or >  2 weeks (82%), then 
followed by ≥  3 weeks on duvelisib. PFS  was also similar between subjects with ≥  1 DI and  
those without  DI for > 1 week or  > [ADDRESS_517890]  3 months  of therapy  (median PFS:  > 
1 week, 17.8 vs 16.3 months;  > 2 weeks, 17.8  vs 16.3  months)  (Flinn 2019 ). These data  support 
the hypothesis that prespecified [ADDRESS_517891]  
efficacy. Based  on these results,  the VS -0145 -229 study  will examine the effects of prespecified 
2-week dose holidays  on tumor  responses  (i.e., is  uninterrupted dosing  required in early cycles  to 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  24 of 80  
 achieve  responses,  or can comparable  tumor  responses be  achieved  starting  with alternating  
2-week periods of dosing  and holidays?) and  safety/tolerability (i.e., will  the holidays reduce the 
frequency, severity, and/or duration of AEs, allowing  subjects to stay on treatment longer?).  
4.3. Justification  for Dose  
The duvelisib 25 mg  BID dose was selected as the current  Recommended Phase 2 Dose (RP2D) 
based on the pharmacokinetics  (PK),  pharmacodynamics,  clinical  activity,  and safety observed in 
a Phase 1 dose escalation study (IPI -145-02) in subjects with hematologic malignancies,  
including  iNHL. The efficacy, safety,  and tolerability of this RP2D was confirmed in a Phase 2 
study (IPI -145-06) in subjects with iNHL  and is currently the approved  label  dose for CLL/SLL 
and FL patients. Please see the IB  for detailed descriptions  of duvelisib clinical  study results  and 
the selection of the RP2D.  
4.4. End of Study  Definition  
A subject  is considered to have completed  the study if  he/she has  completed the last  scheduled 
procedure shown in the Schedule of Activities (SoA) (Section 1.3). 
The end of the study is  defined as  the date of  the last  scheduled  procedure  shown  in the SoA 
(Section 1.3) for the last subject in the study globally. This will occur [ADDRESS_517892] is randomized.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  25 of 80  
 5. STUDY  POPULATION  
Prospective approval  of protocol  deviations to recruitment  and enrollment  criteria, also known  as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion  Criteria  
Subjects  may be eligible  for inclusion  in the study  if they meet  the following  criteria:  
1. Male  or female  subjects ≥  18 years  of age 
2. Histologically confirmed  diagnosis  of iNHL. Histologic subtypes  include FL  Grades  1 to 
3a, marginal zone lymphoma (splenic, nodal, or extranodal), or SLL  
3. Must  have  received  at least [ADDRESS_517893] 
1 bidimensionally measurable lesion ≥  1.5 cm (which  has not  been previously  irradiated), 
according  to 2007 revised  IWG criteria ( Cheson 2007 ), and be a candidate  for a 
subsequent  line of therapy  
5. Must  have  adequate  organ  function  defined  by [CONTACT_410582]:  
a. Absolute  neutrophil  count  (ANC)  ≥ 1.0 × 109/L 
b. Platelet  count  ≥ 75 × 109/L 
c. Hemoglobin  ≥ 8 g/dL 
d. Estimated creatinine clearance  (eCCr)  ≥ 60 mL/min, as determined by  [CONTACT_16424] - 
Gault method ( Cockcroft 1976 ) 
e. Total  bilirubin ≤ 1.5 × upper  limit  of normal  (ULN)  (exception:  subjects  with 
Gilbert's Syndrome may have a bilirubin > 1.5 × ULN)  
f. Aspartate  transaminase  (AST)/serum  glutamic -oxaloacetic  transaminase  (SGOT)  and 
alanine  aminotransferase (ALT)/serum  pyruvic transaminase (SGPT)  ≤ 3.0 × ULN  
6. Eastern  Cooperative  Oncology  Group  (ECOG)  performance  status  ≤ 2 
7. Male and female subjects of reproductive potential (i.e., not surgically sterile or female 
subjects who are not  postmenopausal)  must  be willing  to use highly effective methods  of 
contraception (see Section  10.4) for the duration  of the study intervention  and for  
[ADDRESS_517894] dose of duvelisib  
8. Negative  serum  human  chorionic  gonadotropin  (hCG)  pregnancy  test within  [ADDRESS_517895]  is a woman of childbearing  potential 
(WCBP) (defined in Section 10.4) 
9. Signed  and dated  institutional  review  board  (IRB)/independent  ethics  committee  
(IEC) -approved informed consent  form  before  any study specific -screening  procedures 
are performed  
5.2. Exclusion  Criteria  
Subjects  will be excluded  from  the study  if they meet  any of the following  criteria:  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  26 of 80  
 1. Anticancer treatment, major surgery, or use of any investigational  drug within 28 days 
before the start of study  intervention;  palliative  radiation  therapy  is allowed if >  [ADDRESS_517896] dose of study  interventions and any  toxicity is Grade ≤ 1  
2. Clinical  or histological  evidence of transformation to a more aggressive subtype of 
lymphoma or grade 3b FL or Richter’s transformation or CLL  
3. Received  prior  allogeneic  hematopoietic  stem  cell transplant  (HSCT)  
4. Previous  treatment  with a PI3K  inhibitor  
5. Known  hypersensitivity  to duvelisib  and/or  its excipi[INVESTIGATOR_840]  
6. History or concurrent  condition of interstitial  lung disease of any  severity and/or severely 
impaired lung function  
7. Prior  history  of drug-induced  colitis  or drug-induced  pneumonitis  
8. History  of tuberculosis  treatment  within  the 2  years  prior  to randomization  
9. Administration of  a live or  live attenuated  vaccine within  6 weeks  of randomization  
10. Ongoing  treatment  with chronic immunosuppressants (e.g., cyclosporine) or systemic 
steroids > 20 mg of prednisone (or equivalent) per day  
11. Ongoing  treatment  for systemic  bacterial,  fungal,  or viral infection  at screening  
• Note:  Subjects on antimicrobial, antifungal, or antiviral  prophylaxis are not 
specifically excluded if all other inclusion/exclusion criteria are met  
12. Active cytomegalovirus  (CMV)  or Epstein -Barr virus  (EBV)  infection (i.e., subjects  with 
detectable viral load)  
13. Unable to receive prophylactic  treatment  for pneumocystis, herpes simplex  virus (HSV), 
or herpes zoster (VZV) at screening  
14. Infection  with hepatitis  B, hepatitis  C, or human  immunodeficiency  virus  (HIV)  
• Subjects with a positive hepatitis B  surface antigen [HBsAg]  or hepatitis C  antibody 
[HCV Ab] will  be excluded  
• Subjects with a positive hepatitis B core antibody (HBcAb) must have negative 
hepatitis B  virus (HBV)  deoxyribonucleic acid  (DNA)  to be eligible and must  be 
periodically monitored for HBV reactivation by [CONTACT_76404]  
• Investigators who strongly believe that a positive HBcAb is false  due to passive 
immunization from  previous immunoglobulin  infusion  therapy  should discuss the 
potential to defer HBV prophylaxis with the Medical Monitor  
15. Concurrent administration of medications  or foods that are strong  inhibitors  or inducers 
of cytochrome P450 3A  (CYP3A). No prior  use within [ADDRESS_517897] with diarrhea, refractory nausea, 
vomiting, or any other condition that will interfere  significantly with drug  absorption  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  27 of 80  
 17. Central  nervous system non -Hodgkin lymphoma  (NHL);  lumbar puncture not  required 
unless central nervous system involvement is clinically suspected  
18. Baseline QTcF  > 500 ms  (average of triplicate readings). NOTE:  This criterion does  not 
apply to subjects with a right or left bundle branch block.  
19. Concurrent  active malignancy other  than non -melanoma skin  cancer  or carcinoma in situ 
of the cervix, bladder cancer, or prostate  cancer not requiring  treatment. Subjects with 
previous malignancies are eligible if they have been disease -free for 2 years or more.  
20. History of chronic liver  disease, veno -occlusive disease/sinusoidal  obstruction syndrome, 
alcohol abuse, or illicit drug use  
21. History  of stroke,  unstable  angina,  myocardial  infarction,  or ventricular  arrhythmia  
requiring  medication or mechanical  control  within the last  [ADDRESS_517898]  dose of 
study intervention  
22. Unstable  or severe  uncontrolled  medical  condition  (e.g.,  unstable  cardiac  function,  
unstable pulmonary condition). Any  important  medical  illness or abnormal  laboratory 
finding that would, in the Investigator’s judgment,  increase  the subject’s risk to 
participating in this study.  
23. Female  subjects  who are pregnant  or breastfeeding  
5.3. Lifestyle  Considerations  
• Male  and female subjects  of reproductive potential  (i.e., not surgically  sterile  or 
female subjects who  are not  postmenopausal)  must  use highly effective contraception 
for the duration of  the study intervention  and for at least [ADDRESS_517899] dose 
of duvelisib. Please see Section 10.4 for detailed contraceptive requirements.  
• Subjects  should  be advised  to use appropriate  protective  measures  to minimize  
exposure to direct  sunlight  or ultraviolet  light sources during  the treatment  period and 
for at least [ADDRESS_517900] dose of duvelisib. Please see the IB for additional 
details on the potential for phototoxicity.  
• Refrain from consumption of grapefruit juice and St. John’s Wort, and other foods 
and herbal  products that  are strong  inhibitors or inducers of CYP3A during  treatment 
with duvelisib. Please see Section 6.6.3  for additional information  on restrictions on 
the use of CYP  3A inhibitors, inducers, and  substrates, and  Section 10.2 for lists of 
CYP3A inhibitors, inducers, and substrates. The IB contains  additional details on 
potential interactions with foods.  
5.4. Definition  of Enrolled  
"Enrolled"  means a subject's agreement  to participate in a clinical  study following  completion  of 
the informed consent process. Potential subjects who are pre -screened  for the purpose of  
determining  eligibility for  the study but  do not  sign an informed  consent  form (ICF)  are not 
considered enrolled.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  28 of 80  
 5.5. Screen  Failures  
Screen failures are defined  as subjects who  consent  to participate in the clinical  study but  are not 
subsequently randomly assigned to study intervention. A minimal set of screen failure  
information is required  to ensure transparent  reporting  of screen  failure subjects to meet  the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities. Minimal information  includes demography, 
screen failure details, eligibility criteria, and any serious adverse event (SAE).  
Individuals  who do not  meet  the criteria for  participation in this  study (screen failure)  may be 
rescreened. A subject  who is rescreened  is not  required  to sign another  ICF if the rescreening  
occurs  within 30 days  from the previous  ICF signature [CONTACT_568]. Please note that  repeating  of clinical 
laboratory assessments during screening does not constitute rescreening.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  29 of 80  
 6. STUDY  INTERVENTION  
Study  intervention  is defined  as any investigational  intervention(s),  marketed  product(s),  
placebo, or  medical  device(s)  intended to be administered to a study subject  according  to the 
study protocol.  
6.1. Study  Intervention(s)  Administered  
Table  4: Study  Intervention  Arms  
 
 Arm  1 Arm  2 
Intervention  Name  [CONTACT_410615] -white  crystalline  powder  
Dose  Formulation  Capsule  
Unit  Dose  Strength(s)  25 mg 
15 mg (dose  reductions  only)  
Formulation  Excipi[INVESTIGATOR_410548]  (diluent, glidant, disintegrant, and  lubricant) that are  listed  in 
the [LOCATION_002] (US) Food and Drug Administration (FDA) Inactive 
Ingredients Database for approved drug products and/or Generally 
Regarded as Safe (GRAS).  
Dosage  Level(s)  and 
Frequency  [ADDRESS_517901] (IMP) or Non - 
Investigational Medicinal 
Product (NIMP)  IMP 
Sourcing  Provided  by [CONTACT_410583].  
Current/Former  Name(s)  or 
Alias(es)  VS-0145,  IPI-145 
6.2. Administration  
Duvelisib should be  swallowed whole  with a  glass  of water  (approximately 8 ounces  or 240 mL). 
Advise subjects not  to open, break,  or chew the capsules.  Duvelisib  may be administered  without 
regard to meals, however, subjects must  avoid  grapefruit  and grapefruit  juice while on duvelisib.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  30 of 80  
 Refer to the Pharmacy Manual  for additional  instructions regarding  study  intervention 
administration.  
6.3. Preparation/Handling/Storage/Accountability  
Dispensing  and storage instructions for duvelisib will be provided in the Pharmacy Manual. On 
receipt  at the investigative site, duvelisib should remain in the packaging  as provided  until use or 
dispensation. The packaged  product  should be  stored at  the investigative site at  20° to 25°C (68° 
to 77°F), with  excursions permitted at 15° to 30°C (59° to 86°F). Temperature excursion  
procedures  are provided  in the Pharmacy  Manual.  Expi[INVESTIGATOR_410549].  
Only subjects  enrolled in the study may  receive  study intervention and  only authorized site staff 
may supply or administer study  intervention. All study intervention must be stored in a secure, 
environmentally controlled, and  monitored  (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the Investigator and authorized site staff.  
The Investigator,  institution,  or the head  of the medical  institution  (where  applicable)  is 
responsible for study intervention  accountability, reconciliation,  and record maintenance  (i.e., 
receipt, reconciliation, and final disposition records).  
Further  guidance and information  for the final  disposition  of unused study interventions are 
provided in the Pharmacy Manual.  
6.4. Measures  to Minimize  Bias:  Randomization  and Blinding  
This is an open -label  randomized study. Subjects  will be stratified by  [CONTACT_410580][INVESTIGATOR_014] 
(1 or  > 1), bulky disease status (longest  diameter  of baseline  lesion <  5 cm or  ≥ 5 cm) and time 
since last recurrence (≥ 24 months or < 24 months).  
Subjects  will be assigned a unique number  in ascending  numerical  order  at each study  site. This 
is an open -label study; however, the specific arm for a subject will be assigned using  an 
interactive  web response  system (IWRS).  The site  will contact  [CONTACT_410584].  The site will  record the arm  assignment  on the 
applicable case report form (CRF). Potential bias will be reduced by [CONTACT_385014].  
6.5. Study  Intervention  Compliance  
When subjects  are dosed at  the site, they will  receive study intervention directly  from  the 
Investigator or designee, under medical supervision. The date  and time of each dose  
administered  in the clinic  will be recorded  in the source  documents  and recorded  in the CRF.  The 
dose of study intervention  and study subject identification will be confirmed  at the time of  
dosing  by a member  of the study site staff  other  than the person administering  the study 
intervention.  
When subjects self -administer study intervention  at home,  compliance  with study intervention 
will be assessed at each visit. Compliance  will be assessed by  [CONTACT_410585] (first  
year on treatment  only)  and counting  returned capsules  during  the site visits  and documented in 
the source documents and CRF. Deviation(s) from the prescribed dosage regimen should  be 
recorded in the CRF.  
Protocol  VS-[ADDRESS_517902] be 
maintained and reconciled  with study intervention  and compliance  records. Intervention  start and 
stop dates, including  dates for  intervention delays and/or  dose reductions  will also be recorded in 
the CRF.  
6.6. Concomitant  Therapy  
Any other medication (e.g., supportive care) that is considered  necessary for the subject’s 
welfare and is  not expected  to interfere with the evaluation of  duvelisib may  be given at  the 
discretion of the Investigator.  
Any medication that  the subject  is receiving  at the time of enrollment  or receives during  the 
study must be recorded along with:  
• Reason  for use 
• Dates of  administration  including  start and end dates  
• Dosage  information  including  dose and frequency  
The Medical  Monitor  should be contact[CONTACT_410586].  
6.6.1. Required and Recommended  Prophylaxis  
[IP_ADDRESS].  Antimicrobial  and Antiviral  Prophylaxis  
Based  on the duvelisib  clinical  experience  to date the following  are required  or recommended:  
• Subjects are required to receive pneumocystis prophylaxis concomitant with study 
intervention treatment per institutional guidelines.  Following  completion  of duvelisib 
treatment, continue prophylaxis until the absolute  CD4+ T -cell count is greater than  
200 cells/μL.  
• HSV and VZV  infections  have been  observed with duvelisib;  therefore, herpes 
(HSV/VZV) prophylaxis concomitant with treatment is recommended, per 
Investigator discretion according to institutional guidelines.  
• Subjects  with a  history of CMV  infection/reactivation  or viremia  should be  monitored 
for reactivation by [CONTACT_940] (PCR) or antigen test at least monthly.  
Prophylactic treatment  per institutional  guidelines is recommended  for subjects 
considered by [CONTACT_410587].  
• Antimicrobial prophylaxis and  pneumococcal pneumonia vaccine  are recommended 
for subjects with history of or considered at high risk for infections and  during  
periods of severe  neutropenia. Choice of  antimicrobial  agent  (antifungal, antibiotic, 
antiviral) is per Investigator discretion, but the restrictions on the use of CYP3A  
inducers,  inhibitors,  and substrates  should  be considered  (see Section  6.6.3 ). 
6.6.2. Supportive  Care  and Management  of Toxicities  
Supportive  care should  be provided  as clinically  indicated.  Granulocyte  colony -stimulating  
factor  (G-CSF)  may be used according  to the American  Society  of Clinical  Oncology  (ASCO)  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  32 of 80  
 guidelines ( Smith 2015 ). Transfusions may be  used at  any time as clinically indicated,  and 
according  to ASCO  guidelines. Subjects  on a stable dose of  erythropoietin to treat  baseline 
anemia may continue this therapy at this dose.  
Recommendations  for the management  of non-hematologic  and hematologic  AEs with 
supportive care, treatment  hold,  dose reduction, or  discontinuation  of duvelisib are found  in 
Table 5 . Additional information regarding  management of toxicities can be found  in the 
Summary of Data and Guidance  to the Investigator section  of the IB.  
Table  5: Recommendations  for the Management  of Toxicities  
 
Toxicity  Adverse  Reaction  Grade  Recommended  Management  
Non-hematologic  Adverse  Reactions  
 
 
 
 
Infections  Grade  3 or higher  infection  • Withhold  duvelisib  until resolved  
• Resume  at the same  or reduced  dose (see Table  8) 
Clinica  l CMV  infection  or 
viremia (positive  PCR or 
antigen  test) • Withhold  duvelisib  until resolved  
• Resume  at the same  or reduced  dose (see Table  8) 
• If duvelisib is  resumed,  monitor  subjects  for CMV 
reactivation  (by [CONTACT_410588]) at least monthly  
PJP • For suspected  PJP, withhold  duvelisib  until evaluated  
• For confirmed  PJP, discontinue duvelisib  
 
 
 
 
 
 
 
 
 
 
 
 
Non-infectious 
Dia rrhea  or colitis  Mild/moderate  dia rrhea  
(Gra de 1-2, up to 6 stools  per 
day over  baseline)  and 
responsive  to antidiarrheal  
agents, 
OR 
Asymptomatic  (Gra de 1) 
colitis   
 
• No change  in dose 
• Initiate  supportive  therapy  with antidiarrheal  agents 
as appropriate  
• Monitor  at lea st weekly  until resolved  
Mild/moderate  dia rrhea  
(Gra de 1-2, up to 6 stools  per 
day over  baseline)  and 
unresponsive  to antidiarrheal 
agents  • Withhold  duvelisib  until resolved  
• Initiate  supportive  therapy  with enteric  acting 
steroids  (e.g.,  budesonide)  
• Monitor  at lea st weekly  until resolved  
• Resume  at a reduced  dose (see Table  8) 
Abdominal  pain,  stool  with 
mucus  or blood,  change  in 
bowel  habits,  peritoneal 
signs,  
OR 
Severe  dia rrhea  (Gra de 3, 
> 6 stools  per day over 
baseline)   
• Withhold  duvelisib  until resolved  
• Initiate  supportive  therapy  with enteric  acting 
steroids  (e.g.,  budesonide)  or systemic  steroids  
• Monitor  at lea st weekly  until resolved  
• Resume  at a reduced  dose (see Table  8) 
• For recurrent  Gra de 3 dia rrhea  or recurrent  colitis  of 
any grade,  discontinue duvelisib  
Life-threatening  • Discontinue  duvelisib  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  33 of 80  
  
Toxicity  Adverse  Reaction  Grade  Recommended  Management  
 
 
 
 
 
 
 
Cutaneous  reactions   
Gra de 1-2 • No change  in dose 
• Initia  te supportive  care with emollients,  anti- 
histamines  (for pruritus),  or topi[INVESTIGATOR_103993]  
• Monitor  closely  
 
 
 
Gra de 3 • Withhold  duvelisib  until resolved  
• Initia  te supportive  care with emollients,  anti- 
histamines  (for pruritus),  or topi[INVESTIGATOR_103993]  
• Monitor  at lea st weekly  until resolved  
• Resume  at reduced  dose (see Table  8) 
• If severe  cutaneous  reaction  does not improve, 
worsens,  or recurs,  discontinue  duvelisib  
Life-threatening  • Discontinue  duvelisib  
SJS, TEN,  DRESS  (any 
grade)  • Discontinue  duvelisib  
 
 
 
Pneumonitis  without 
suspected  infectious 
cause   
 
Moderate  (Gra de 2) 
symptomatic  pneumonitis  • Withhold  duvelisib  
• Treat  with systemic  steroid  therapy  
• If pneumonitis  recovers  to Grade  0 or 1, duvelisib 
may  be resumed  at reduced dose  (see Table  8) 
• If non -infectious  pneumonitis  recurs  or subject  does 
not respond  to steroid  therapy,  discontinue  duvelisib  
Severe  (Gra de 3) or life- 
threatening  pneumonitis  • Discontinue  duvelisib  
• Treat  with systemic  steroid  therapy  
 
 
 
 
ALT/AST  eleva  tion  
3 to 5 × ULN  (Grade  2) • Maintain  duvelisib  dose 
• Monitor  at least weekly  until return  to 
< 3 × ULN  
 
 
> 5 to 20 × ULN  (Grade  3) • Withhold  duvelisib  and monitor  at lea st weekly  until 
return to <  3 × ULN  
• Resume  duvelisib  at same  dose (first  occurrence)  or 
at a reduced  dose for subsequent  occurrence  (see 
Table  8) 
> 20 × ULN  (Gra de 4) • Discontinue  duvelisib  
Hematologic  Adverse  Reactions  
Febrile  neutropenia  Gra de 3-4 • Interrupt  duvelisib  until afebrile  and resolution  of 
Grade  3 or Grade  4 neutropenia  to Grade  ≤2 
 
 
 
Neutropenia  ANC  0.5 to 1.0 Gi/L • Maintain  duvelisib  dose 
• Monitor  ANC  at least weekly  
 
 
ANC less  than 0.5 Gi/L • Withhold  duvelisib  
• Monitor  ANC  until > 0.5 Gi/L 
• Resume  duvelisib  at same  dose (first  occurrence)  or 
at a reduced dose  for subsequent  occurrence  
(see Table  8) 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  34 of 80  
  
Toxicity  Adverse  Reaction  Grade  Recommended  Management  
 
 
 
 
Thrombocytopenia  Platelet  count  25 to 
< 50 Gi/L (Gra de 3) with 
Grade  1 bleeding  • No change  in dose 
• Monitor  platelet  counts  at least weekly  
Platelet  count  25 to 
< 50 Gi/L (Gra de 3) with 
Grade  2 bleeding  
or 
Pla telet count  < 25 Gi/L 
(Gra de 4) • Withhold  duvelisib  
• Monitor  platelet  counts  until ≥ 25 Gi/L and 
resolution  of bleeding  (if applicable)  
• Resume  duvelisib  at same  dose (first occurrence)  or 
resume  at a reduced  dose for  subsequent  occurrence 
(see Table  8) 
Abbrevia  tions:  ALT: alanine aminotransferase; ANC:  absolute  neutrophil  count;  AST: aspartate transaminase; 
CMV:  cytomegalovirus;  DRESS:  drug reaction  with eosinophilia  and systemic  symptoms;  Gi:1 x 109; PCR: 
polymerase chain reaction; PJP: Pneumocystis  jiroveci  pneumonia;  SJS: Stevens -Johnson  syndrome; TEN: toxic 
epi[INVESTIGATOR_81501]; ULN: upper  limit of normal.  
6.6.3. Concomitant Therapi[INVESTIGATOR_410550] 6:   Prohibited  Concomitant  Therapi[INVESTIGATOR_410551], the use of live or live attenuated vaccines  is prohibited 
within  [ADDRESS_517903] dose of study drug.  
The use of inactivated (or killed) vaccines (such as pneumococcal 
pneumonia vaccine) is allowed during the study, however subjects and their 
physicians should  be aware that the  effectiveness of any vaccine 
administered  concomitantly  with duvelisib  may be diminished. The  ability  to 
generate an immune response to  any vaccine following the administration of 
duvelisib has not been studied.  
Immunosuppressants  Subjects are not to receive ongoing treatment with chronic 
immunosuppressants  (e.g., cyclosporine) or systemic  steroids  for >  1 week  at 
doses > the equivalent of 20 mg prednisone QD.  
Note: Acute treatment for underlying autoimmune disorders (e.g., reactive 
airway  disease, rheumatoid  arthritis, etc.) with  corticosteroid  doses  > 20 mg 
prednisone or equivalent QD for ≤ 1 week is permitted during the study.  
Corticosteroid doses  of ≤ 20 mg prednisone  or equivalent QD are  permitted 
during the study for physiological replacement or chronic treatment for 
underlying autoimmune  disorders  (e.g., reactive  airway disease, rheumatoid 
arthritis, etc.).  
Other  Anticancer  Therapy 
or Investigational Agents  During  study  intervention period, subjects  are not to  receive  any additional 
anticancer therapy or other investigational agents not outlined in the 
protocol.  
Protocol  VS-[ADDRESS_517904]  of medications and foods known to inhibit  
(Table  15) or induce  (Table  16) CYP3A. Please  note that these tables do not 
provide  a comprehensive  list of all  medications  which  may modulate  CYP3A 
activity.  
Abbreviations:  CYP3A:  cytochrome  P450  3A; QD: once daily.  
Table  7: Concomitant  Therapi[INVESTIGATOR_014]:  Use with Caution  
 
Concomitant  Therapy: 
Use with Caution  Guidance  
Medications  or Foods  that 
Weakly or Moderately 
Inhibit or Induce  
CYP3A4  Please discuss use  of weak or moderate  CYP3A  inhibitors  and inducers  with 
the Medical Monitor.  
Section 10.[ADDRESS_517905] of medications and foods known to inhibit 
(Table  15) or induce  (Table  16) CYP3A. Please  note that these tables do not 
provide  a comprehensive  list of all  medications  which  may modulate  CYP3A 
activity.  
Medications that are 
Substrates  of CYP3A  Co-administration with duvelisib decreases AUC of a sensitive CYP3A4 
substrate  which  may decrease the  efficacy  of these drugs. Consider finding 
an alternative drug that is  not a substrate of CYP3A4. Table [ADDRESS_517906] of all 
medications which may be substrates of CYP3A. The Sponsor should be 
contact[CONTACT_410589]3A substrates.  
Abbreviations:  AUC:  area under  the curve;  CYP3A:  cytochrome  P450  3A; QD: once daily.  
6.6.4. Contraception  and Pregnancy  
The effects  of duvelisib  on conception,  pregnancy,  and lactation  are unknown.  
At Screening, all  male and female subjects  of reproductive potential  (i.e., not  surgically sterile or 
female subjects who  are not  postmenopausal) must  be willing  to use highly effective  methods of 
contraception for the duration of the study  intervention  and for [ADDRESS_517907] dose  of 
duvelisib. See Section 10.4 (Appendix 4) for Contraceptive  Guidance  including examples of  
highly effective contraceptive methods.  Pregnancy  testing  will be performed  throughout  the 
study as shown in SoA ( Table 1 ). 
6.6.5. COVID -[ADDRESS_517908] received, or  receive while active in the trial, a regulatory -approved  COVID - 
19 vaccine may participate in the study with no restrictions. Any vaccine -related  AEs reported 
by [CONTACT_410590].  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  36 of 80  
 6.7. Dose  Modification  
For dose modifications and dose level  recommendations refer to Table 8 . Duvelisib may  be held 
up to 42 days  for toxicity. Doses  held for  > [ADDRESS_517909] who requires  a dose level reduction to  
below  15 mg  BID due to treatment -related toxicities  will be permanently  discontinued from 
duvelisib treatment.  
If duvelisib treatment  is permanently discontinued  due to an AE, subjects  should be followed  for 
disease response and survival as outlined in the SoA (Table 1 ). 
Dosing  levels  for duvelisib  are shown  in Table  8. 
Table  8: Duvelisib Dosing  Levels  
 
Dose  Level  Duvelisib  Dosing  Levels  
[ADDRESS_517910]  is unable  to tolerate  15 mg BID 
Abbrevia  tions:  BID:  twice  daily  
Subjects  who have  a dose  reduction  due to  a toxicity  will not be eligible  for a dose  re-escalation.  
6.8. Intervention  after  the End of the Study  
If the study is ended prior to all  subjects discontinuing  treatment, any subject  continuing  to 
receive benefit  will be provided the opportunity to continue  to receive duvelisib.  Long -term 
continued treatment  may be provided  via an expanded  access  program consistent  with local 
regulations, such as the Secura Bio NPP.  
Protocol  VS-[ADDRESS_517911]  DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
Duvelisib  will be discontinued  for any of the following  reasons:  
• Subject withdrawal  of informed  consent  
• Protocol -specified  disease  progression  
• Clinical  deterioration  (at the discretion  of the Investigator)  
• Study intervention interruption for  > 42 days  due to duvelisib -related toxicity (unless 
approved by [CONTACT_410591])  
• Unacceptable  toxicity  
• Pregnancy  
• Termination  of the study  by [CONTACT_1034]  
• Death  
• Other  reasons,  including  major  protocol  violation  or noncompliance  
The Investigator  must  determine the primary reason for  a duvelisib discontinuation  and record 
this information on the CRF.  
See the SoA for  data to be collected at  the time of discontinuation of  study  intervention and  for 
any further evaluations that need to be completed.  
7.2. Subject  Withdrawal  from  the Study  
• A subject  may withdraw  from the study  at any time at  his/her  own request  or may be 
withdrawn at any time at the discretion of the Investigator for safety,  behavioral,  
compliance,  or administrative  reasons.  
• At the time of withdrawing  from  the study,  if possible, an  End of Treatment  (EoT)  
Visit  should  be conducted,  as shown  in the SoA.  See SoA  (Table 1 ) for data to  be 
collected at  the EoT  Visit and follow -up, and for  any further  evaluations that  need  to 
be completed. Additional visits may be conducted as necessary for any abnormal  
findings  that require  medical  follow -up. 
• The subject  will be permanently discontinued from the study intervention  and 
withdrawn from the study at that time.  
• If the subject  withdraws  consent  for disclosure of  future information, the Sponsor 
may retain and continue to use any  data collected before such  a withdrawal of  
consent.  
• If a subject  withdraws from the study, he/she may request  destruction of any samples 
taken and not  tested,  and the  Investigator  must  document  this in the  site study records.  
Protocol  VS-[ADDRESS_517912]  fails to return to the clinic for  a required study 
visit:  
• The site  must  attempt  to contact  [CONTACT_410592]/or should  continue in 
the study.  
• Before a subject  is deemed lost  to follow -up, the Investigator  or designee must  make 
every effort  to regain contact  [CONTACT_1155]. These contact  [CONTACT_14386] (e.g., 3 phone 
calls followed by a certified  letter) should be documented in the subject’s medical 
record.  
• Should the subject  continue  to be unreachable,  he/she will  be considered  to have 
withdrawn from the study.  
Discontinuation  of specific  sites or of the study  as a whole  are described  in Section  10.6.8 . 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  39 of 80  
 8. STUDY  ASSESSMENTS  AND  PROCEDURES  
• Study procedures  and their  timing  are summarized  in the SoA  (Table 1  and Table 2 ). 
Protocol waivers or exemptions are not allowed.  
• Urgent safety concerns should be discussed with the Sponsor immediately upon 
occurrence or  awareness  to determine if  the subject  should continue or  discontinue 
study intervention.  
• Adherence to the study design requirements,  including  those specified  in the SoA, is 
essential and required for study conduct.  
• All screening  evaluations  must  be completed and reviewed to confirm that  potential 
subjects meet all eligibility  criteria. Repeat lab assessments during the screening  
period do not  constitute rescreening.  The Investigator  will maintain a screening  log to 
record details of all  subjects screened  and to confirm eligibility or record reasons for 
screen failure, as applicable.  
• Procedures  conducted  as part of the subject’s  routine clinical  management  (e.g.,  blood 
count) and obtained  before  signing  of the ICF may be used for screening  or baseline 
purposes provided the procedures met the protocol -specified criteria and were  
performed  within  the time frame  defined  in the SoA.  
• The maximum amount  of blood collected from each subject  over the duration  of the 
study, including  any extra assessments that  may be required, will  be described  in the 
ICF. Repeat  or unscheduled  samples may  be taken  for safety reasons or for technical 
issues with the samples.  
8.1. Efficacy  Assessments  
Assessment of disease response  and progression status  in all subjects will be evaluated by [CONTACT_132068]  2007 IWG criteria ( Cheson 2007 ) and  2014  Lugano criteria ( Cheson 2014 ). 
Response and progression will  be evaluated using  the following  procedures, as  indicated in the 
SoA ( Table 1 ). 
• Focused physical  examination (PE) (including  assessment  of liver and spleen and 
review of disease -related constitutional symptoms) (see Section [IP_ADDRESS] ) 
• Imaging  scans of  chest,  abdomen,  and pelvis  (see Section  8.1.1 ) 
• Bone  marrow  biopsy/aspi[INVESTIGATOR_337]  (see Section  8.1.2 ) 
These evaluations will be done until progressive disease (PD) is documented,  other anticancer 
therapy is  initiated, or  death occurs. For  subjects  who discontinue study intervention  for reasons 
other than radiologic disease progression, response assessments will be performed  during  long- 
term follow -up (Section 8.1.4 ). 
8.1.1. Imaging  Scans  
All subjects require CT or 18Fluoro -2-deoxy -d-glucose (FDG) positron emission tomography 
(PET) -CT (PET -CT) scans of the chest, abdomen, and  pelvis.  Magnetic resonance imaging 
(MRI)  may be used instead of  CT scans  if CT cannot  be done, but  the same  method  must  be used  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  40 of 80  
 throughout  the study.  Other  scans  may be performed (e.g.,  neck/head)  if clinically indicated or  if 
the area is a site of known disease.  Any new abnormal findings outside disease  measurements 
should be captured as an AE.  
8.1.2. Bone  Marrow  Biopsy/Aspi[INVESTIGATOR_410552] a bone marrow/aspi[INVESTIGATOR_410553] [ADDRESS_517913]  of care, 
the pathology report will be provided to the Sponsor. If a radiologic CR according  to 2007  
revised IWG criteria ( Cheson 2007 ) is observed  during  the course  of the study, then  a bone 
marrow  biopsy should be done to confirm a CR.  The pathology report  will be provided to the 
Sponsor.  
8.1.3. Investigator  Assessment  of Response  and Progression  Status  
Assessment  of response  and progression  status  will be evaluated  by [CONTACT_410593] (Table 1 ). Assessment  of response 
and progression status in all subjects will be evaluated using  the definitions from the 2007  
revised IWG criteria ( Cheson 2007 ) for clinical  decision -making  and assessment  of response. 
Secondarily, response will also be assessed  using  the 2014  Lugano criteria ( Cheson 2014 ). 
Please  see Section  10.1 for detailed  descriptions  of these  response  criteria.  
8.2. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA (Table  1). Additional  
visits may  be conducted  as necessary  for any abnormal  findings  that require  medical  follow -up. 
8.2.1. Physical  Examinations  and Vital  Signs  
[IP_ADDRESS].  Full Physical  Examination  
The full  PE will include assessment  of liver/spleen size,  clinical  assessment  of tumor masses (if 
evaluable by [CONTACT_153056]), review of disease -related constitutional  symptoms (B  symptoms:  symptoms  of 
fever [i.e., temperature > 38°C/100.4°F] without evidence of infection, weight loss, and  
drenching  night  sweats  without  evidence  of infection),  neurologic  exam,  height,  and weight.  
Any pre-existing  PE abnormality  deemed  clinically  significant  by [CONTACT_410594].  Any PE  abnormality that  emerges  or has worsened 
after signing  of the ICF and that is assessed as clinically significant by [CONTACT_410595]. 
[IP_ADDRESS].  Focused  Physical  Examination  
Each focused  PE is to  include assessment of liver and spleen  size, clinical assessment of tumor 
masses and evaluation  for the presence of  disease -related constitutional  symptoms (B  symptoms: 
symptoms of fever  [i.e., temperature >  38°C/100.4°F]  without  evidence of  infection, weight  loss, 
and drenching night sweats without evidence of infection).  
Results  from the focused PEs  and assessments  of ECOG  performance status  (Section  8.4.1 ) will 
be used for assessment of disease  response and safety.  Additionally, any new or ongoing  
abnormal  findings will  be assessed. Any  new clinically significant  abnormality from baseline 
should be recorded as an AE.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  41 of 80  
 [IP_ADDRESS].  Vital  Signs  
Vital signs  will be measured in a semi -supi[INVESTIGATOR_55848]  [ADDRESS_517914] and will include 
temperature, systolic and diastolic blood pressure,  pulse rate, and respi[INVESTIGATOR_697].  
8.2.2. Electrocardiogram  and Echocardiogram/Multi -gated  Acquisition  Scan  
At Screening,  a standard  12-lead electrocardiogram  (ECG)  will be conducted  following  an 
approximate [ADDRESS_517915] period. QTc measurements (as measured  by [CONTACT_410596])  will 
use the Fridericia’s correction method (QTcF).  
To measure left  ventricular  ejection  fraction  (LVEF), an echocardiogram (ECHO)  or multi -gated 
acquisition (MUGA) scan will be administered at the Screening Visit.  
Additional  ECGs and ECHO/MUGA scans may be performed as clinically  indicated  per 
Investigator’s  judgment.  
8.2.3. Concomitant  Medication  and Procedures  
Concomitant  medications and  procedures will  be assessed  and recorded  in the CRF  during  
Screening  (including  those  occurring  within  30 days prior  to randomization)  and at each visit.  
8.2.4. Clinical  Safety  Laboratory  Assessments  
• See Table [ADDRESS_517916]  of clinical  laboratory tests  to be performed  and the SoA 
(Table 1 ) for the timing and frequency.  
• The Investigator must  review the laboratory report, document  this review, and  record 
any clinically relevant changes occurring  during  the study in the AE section of the 
CRF. The laboratory reports must be filed  with the source  documents. Clinically  
significant  abnormal  laboratory  findings  are those  which  are not associated  with the 
underlying disease, unless judged by  [CONTACT_410597]'s condition.  
• All laboratory tests with values considered  clinically significantly  abnormal  during 
participation in the study or  within [ADDRESS_517917]  dose of  study intervention 
should be repeated  until the values return  to normal or baseline  or are no longer 
considered clinically significant by [CONTACT_410598].  
o If such values do not return to normal/baseline within a period  of time judged 
reasonable by [CONTACT_737], the etiology should be identified, and  the Sponsor 
notified.  
o All protocol -required laboratory  assessments,  as defined  in Table [ADDRESS_517918]  be 
conducted in accordance  with the Laboratory  Manual and  the SoA (Table 1 ). 
o If laboratory values  from  non-protocol -specified laboratory assessments 
performed  at the institution’s local  laboratory require a change in subject  
management  or are considered clinically significant  by [CONTACT_737]  (e.g.,  SAE 
or AE or dose modification), then  the results must be recorded  in the CRF.  
Protocol  VS-[ADDRESS_517919] a causal  relationship with this treatment. An AE  can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or  disease temporally associated  with the use of a medicinal  (investigational)  product, 
whether or not related to the study (investigational) product. This includes an exacerbation of 
pre-existing conditions or events, concurrent illnesses, drug interaction, or the significant  
worsening  of the indication  under  investigation.  Anticipated  fluctuations  of pre-existing  
conditions, including  the disease under study that  does not represent  a clinically significant 
exacerbation or worsening, need not be considered AEs.  
Symptoms  of the disease  under  study/lack  of efficacy/disease  progression  should  not be 
classified as  an AE  if they are within the normal  day-to-day fluctuation or  expected  progression 
of the disease.  
It is the responsibility of the Investigator  to document  all AEs that occur  during  the study.  AEs 
should be reported on the appropriate CRF.  
8.3.2. Definition  of a Serious  Adverse  Event  
An SAE is any untoward medical  occurrence at  any dose (including  after the ICF  is signed and 
prior to dosing) that:  
• Results  in death  
• Is life-threatening  (subject  is at immediate  risk of death  from  the event  as it occurred)  
• Requires  inpatient  or prolongation  of existing  hospi[INVESTIGATOR_059]  
• Results  in persistent  or significant  disability/incapacity  
• Results  in a congenital  anomaly/birth  defect  
Important  medical  events that  may not  result  in death, are not  immediately  life-threatening, or do 
not require hospi[INVESTIGATOR_410554], based  on appropriate medical  
judgment, they may jeopardize the subject  and may require medical  or surgical  intervention  to 
prevent  one of the outcomes listed in this definition. Examples of such  events include  allergic  
bronchospasm requiring  intensive  treatment  in an emergency room or  at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059],  or the development of drug  
dependency  or drug abuse.  
For SAE reporting  purposes,  hospi[INVESTIGATOR_410555]. Hospi[INVESTIGATOR_410556] a TEAE are not  
considered SAEs. Hospi[INVESTIGATOR_059], which  in the opi[INVESTIGATOR_2819], is  unrelated  to the 
study intervention,  and due  to purely non -medical circumstances (e.g., respi[INVESTIGATOR_4594], lack  of a 
caretaker  at home, lack of  transportation  home)  are also not  considered  to be SAEs. PD under 
study (including  signs and symptoms  of progression) if documented  by [CONTACT_410599], should  not be reported as  an SAE  unless  the outcome of  the PD  is fatal during  the study 
or within  the safety  reporting  period  (see Section  8.3.3 , Reporting  of Adverse  Events  and Serious  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  43 of 80  
 Adverse Events). If the malignancy has a fatal outcome during  the study or within the safety 
reporting  period, then the event  should  be reported  using  the term "disease progression"  with a 
Common Terminology Criteria for Adverse  Events (CTCAE) severity of Grade 5.  
Death should not  be reported  as an SAE. The primary reason  for a subject’s death  should be 
reported as an SAE, with death reported as the outcome.  
8.3.3. Reporting  of Adverse  Events  and Serious  Adverse  Events  
The AE reporting  period  begins  from  the time that the subject  signs  the ICF through  and 
including  [ADDRESS_517920] study intervention dose. All subjects with treatment - 
related AEs/SAEs should be observed until resolution or stabilization.  Any SAE occurring after 
the reporting  period must  be promptly reported  if a causal  relationship to the investigational  drug 
is suspected. If  the subject begins a new anticancer therapy, the safety  reporting  period  ends at 
the time the  new treatment  is started, however,  death must  always be reported if it  occurs during 
the AE reporting period irrespective of intervening treatment.  
Elective or previously scheduled  hospi[INVESTIGATOR_31643] -existing  conditions that  have  not 
worsened after initiation of treatment should not be classified  as SAEs. For example, an  
admission  for a previously  scheduled  ventral  hernia  repair  would  not be classified  as an  SAE.  
All AEs should be recorded individually unless, in the opi[INVESTIGATOR_410557], the AEs constitute components of  a recognized  condition, disease,  or syndrome.  In the 
latter  case, the condition,  disease, or syndrome  should be reported rather than each  individual 
sign or symptom. If a constellation  of signs and/or symptoms  cannot be medically characterized 
as a single diagnosis or syndrome at the time of reporting, each  individual event should be  
recorded as an AE  or SAE  as appropriate on the relevant  form(s)  (SAE  Report  Form and/or  AE 
CRF).  If a diagnosis is subsequently  established, it  should  be reported  as follow -up information 
becomes available. If a diagnosis is determined after the reporting  of the constellation  of 
symptoms,  the signs/symptoms  should  be updated  to reflect  the diagnosis.  
Each AE  will be evaluated for  duration, severity, seriousness,  and causal  relationship to the 
investigational  drug. The action taken with study intervention and  the outcome must  also be 
recorded.  
All SAEs, regardless of relationship  to the study intervention, must be reported  immediately 
(within 24 hours of awareness of event  by [CONTACT_10670]) to the Sponsor and  Contract  Research 
Organization (CRO) pharmacovigilance group. Initial SAE notification should be  made by  e- 
mailing or  faxing  the SAE  report  form to the e -mail or fax number  provided  on the SAE  report 
form.  
An initial SAE Report  may be sent  without  the Investigator’s  signature [CONTACT_410616] 
a report signed by [CONTACT_13658] [ADDRESS_517921].  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  44 of 80  
 8.3.4. Severity  of Adverse  Events  
The severity of the AE  will be graded according  to the National  Cancer Institute (NCI) CTCAE, 
version 5.0 (see web page 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50  for details). 
AEs not  listed in the CTCAE should be graded as summarized in Table 9 . 
Table  9: CTCAE  AE Grading  
 
CTC  Grade  Equivalent  To: Definition  
Grade  [ADDRESS_517922] daily activity; no 
treatment or medical intervention is  indicated although this 
could improve the overall well -being or symptoms of the 
subject  
Grade  3 Severe  Inability  to work  or perform normal daily  activity; treatment 
or medical intervention is indicated to improve the overall 
well-being or symptoms; delaying the onset of treatment is 
not putting the survival of the subject at direct risk  
Grade  4 Life-threatening/ 
disabling  An immediate  threat to  life or leading  to a permanent mental 
or physical condition that prevents work or performing 
normal daily activities; treatment or medical intervention is 
required to maintain survival  
Grade  5 Death  AE resulting  in death  
Abbreviations:  AE: adverse event,  CTC:  Common Terminology  Criteria; CTCAE: Common  Terminology 
Criteria for  Adverse Events.  
 
8.3.5. Relationship  of Adverse  Events  to Study  Intervention  
The Investigator  will make a judgment  regarding  whether  or not the AE  was related to study 
intervention, as outlined below:  
• Definitely related:  This category applies when, after  careful  medical  consideration, 
there is almost no consideration of other causation.  
• Probably related:  There is  a clinically plausible time sequence  between  onset  of the 
AE and study intervention administration. The AE is unlikely to be caused  by a 
concurrent  or underlying  illness, other  drugs, or  procedures. If applicable, the AE 
follows a clinically consistent resolution pattern upon withdrawal of study 
intervention.  
• Possibly related: There is a clinically plausible time sequence between  onset of the 
AE and study intervention administration, but  the AE  could also have been caused  by 
[CONTACT_410600], other drugs, or procedures. Information  
regarding  study intervention withdrawal  may be lacking  or unclear.  "Possible"  should 
be used when study intervention administration is one of several biologically  
plausible  causes  of the AE. 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  45 of 80  
 • Unlikely  related: The AE is most likely due to a cause not related to study 
intervention administration. However, association with the study  intervention  cannot 
be completely ruled out.  
• Unrelated: Another cause of the AE is most plausible, and a clinically plausible 
temporal  sequence is inconsistent  with the onset  of the AE  and study intervention 
administration and/or  a causal  relationship is considered  biologically implausible.  
For the purpose of  regulatory reporting  requirements,  causal  relationships of  definite, probable, 
and possible will be considered treatment -related, while unlikely and unrelated will be  
considered  not treatment -related.  
8.3.6. Clinical  Laboratory  Adverse  Events  
A clinical  laboratory AE  is any laboratory  value that  is deemed  clinically significant  by [CONTACT_3786]. The Investigator should decide,  based  upon the AE criteria and the clinical  
condition of the subject,  whether  a change in a laboratory parameter  is clinically significant  and 
therefore represents an AE.  
The following  items  may be considered  when  determining  clinical  significance:  
• Severity  of the laboratory abnormality (i.e.,  greater  than Grade  2 in severity)  
• Laboratory  abnormality  requires a  medical  intervention  
• Laboratory  abnormality  requires  a change  or suspension  of study  intervention  
• Laboratory  abnormality  is accompanied  by [CONTACT_410601]. If a 
medical intervention occurs,  it should be recorded  as a treatment with the abnormal laboratory  
finding  as the AE  (e.g., anemia with treatment  required and blood  transfusion recorded  as a 
procedure, hyperglycemia with treatment required  and change in insulin dose recorded  on 
concomitant  medications).  
If, at  the end of the treatment  phase  with the study intervention, there are pathological  laboratory 
values which were not present at Baseline, further clinical or laboratory  investigations  should  be 
performed  until the values return  to within reference  range or until a plausible explanation  (i.e., 
concomitant disease) is found for the pathological laboratory values.  
8.3.7. Regulatory  Aspects  of Adverse  Event  Reporting  
The Sponsor  is responsible for  submitting  reports of  SAEs associated  with the use of the study 
intervention to the appropriate Regulatory  Authority (e.g., the US FDA), Investigators, and 
IRB/IEC/Central Ethics Committee (CEC) in accordance with all applicable  regulations and 
guidelines.  
It is the  responsibility of the  Investigator  to notify  the IRB of all  SAEs  that occur  at his or her 
site. Investigators will be notified of all suspected, unexpected  serious adverse reactions 
(S[LOCATION_003]Rs; 7 / 15 Day Safety Reports)  that occur  during  any clinical  studies  that are using  the 
investigative compound.  Each site is responsible for notifying  their IRB/IEC/CEC of these 
additional S[LOCATION_003]Rs in accordance with local regulations.  
Protocol  VS-[ADDRESS_517923] taken an overdose and should stop  taking  duvelisib.  
For this  study, overdose  is defined as  a daily dose  of duvelisib higher  than the prescribed  daily 
dose. Overdoses will not be considered SAEs unless the outcome of the overdose meets  
seriousness criteria as defined in Section 8.3.2 . In the event  of an overdose that  causes an SAE, 
the Sponsor  should be notified  within 24 hours of  Investigator’s  knowledge. The subject  should 
be carefully monitored for potential adverse reactions and symptomatic treatment instituted as 
per institutional standards of care. The Investigator will determine if and  when dosing  should 
resume.  
8.3.9. Pregnancy  
Any pregnancy must  be reported to the Sponsor  or designee  within 24 hours  of the Investigator’s 
knowledge of the pregnancy using a Pregnancy Report Form.  
Pregnancy per se is not considered an AE unless there  is cause to believe that the study 
intervention may have interfered  with the effectiveness of a contraceptive medication  or if the 
outcome of the pregnancy  meets SAE  criteria (miscarriage or  congenital  anomaly/birth defect, 
etc.), in which case it should be reported in the same manner and  timelines as an SAE. In  
addition, any infant death or congenital anomaly occurring after 30 days that the Investigator 
suspects  is related to the in -utero exposure to the study intervention should also be  reported  as an 
SAE. Hospi[INVESTIGATOR_14494] a healthy  newborn is not an SAE.  
Since duvelisib has not  been evaluated  in pregnant  or nursing  women,  the treatment  of pregnant 
women  or WCBP who  are not using highly  effective  contraception is contraindicated (see 
Table 18  and Section 10.4 for instructions on pregnancy  testing  and contraception).  
Pregnancies  occurring  in subjects  or partners  of male  subjects  during  the study  intervention  
period until  [ADDRESS_517924]’s last  dose of  study  intervention  are considered  immediately 
reportable events. If a pregnancy occurs in a subject, study intervention  must be discontinued 
immediately. The pregnant woman should be referred to an obstetrician/gynecologist  
experienced  in reproductive  toxicity for further evaluation  and counseling. The Investigator will 
observe the pregnant woman until completion  of the pregnancy and  must notify the Sponsor of 
the outcome within 24 hours of the Investigator’s knowledge of the pregnancy  outcome using  a 
Pregnancy Outcome Form. This notification includes pregnancies  resulting in live, “normal” 
births.  
8.4. Quality  of Life Assessments  
8.4.1. ECOG  Performance  Status  
ECOG  Performance  Status  will be assessed  at Screening.  If the ECOG  Performance  Status  
assessed at  Screening  is performed  within 7 days  of Cycle 1 Day 1, the Screening  assessment  can 
be used and does not  need  to be repeated at  Cycle 1 Day 1 (predose). Please see SoA Table [ADDRESS_517925] self -reported  health -related quality of life (Q οL) will be assessed at Screening, during 
study treatment, and, when possible, upon treatment discontinuation for any reason.  Subject - 
reported health -related  QoL will be assessed using  the EQ -5D-3L questionnaire.  Questionnaire 
should be administered predose and prior to other procedures  during treatment visits.  
8.5. Pharmacokinetics  
• Blood samples  will be collected to evaluate  the PK of duvelisib and  metabolite  IPI- 
656 at the visits and timepoints defined in SoA Table 2 . 
• Predose samples are preferred, therefore on the days that  include  PK assessments the 
morning  dose of duvelisib should be administered in the clinic to facilitate collection 
of samples prior to dosing. However, the sample should still  be collected even  if the 
morning  dose of duvelisib has already been taken. The date and time of the sample  
collection and date and time of  the previous  duvelisib dose must  be recorded for  all 
collected samples.  
• Additional  PK samples beyond  those  listed in SoA (Table 2 ) may be requested  (when 
feasible) for any  unusual  safety  event. (i.e., an AE  different  in type and severity from 
that which is expected in the setting of duvelisib use).  
• Specific instructions on sample collection and  handling  will be provided  in a separate 
Laboratory Manual.  
• Retained duplicate PK  samples  may also be  used to evaluate safety  or efficacy 
aspects related to concerns  arising during or after the study.  
• Genetic  analyses  will not be performed  on these  PK samples.  
• Subject  confidentiality  will be maintained.  
8.6. Pharmacodynamics  
Pharmacodynamic biomarkers will  be assessed  using  blood samples collected at  sampling 
timepoints in the SoA ( Table 2 ) and are described under Biomarkers (Section  8.8). 
8.7. Genetics  
Normal  germline genetic studies are not  evaluated in this study.  Tumor genomic  studies may  be 
conducted as part of exploratory biomarker research (Section 8.8). 
8.8. Biomarkers  
Biomarker  samples will  be collected according  to the SoA  (Table 2 ) and assessments may  be 
conducted to evaluate potential biomarkers as described in Table 10 . 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  48 of 80  
 Table  10:   Biomarker  Samples  and Assessments  
 
Sample  Assessments  
Blood  for pharmacodynamics  Pharmacodynamic  assays  evaluate phosphorylated 
protein levels in several cell types.  
Serum  and plasma  for biomarker  analysis  Protein  (e.g.,  cytokines,  chemokines) and/or  ctDNA  
Blood  for immunophenotypi[INVESTIGATOR_410558]  (e.g.,  B T- funcDNA, 
and/or RNA analysis)  
Stool  for biomarker  analysis  Protein, DNA, and/or RNA  analysis  to evaluate 
correlations with gastrointestinal toxicities  
Archival  tumor  tissue  (if available)  Tumor markers  that may predict  clinical  response  to 
duvelisib.  
PI3K  pathway and/or disease -specific  biomarkers  (e.g. 
PTEN, PI3K isoforms) by [CONTACT_317438]/or in situ hybridization.  
Tumor genomic  studies  may be performed  (e.g. DNA 
sequencing, DNA copy number analysis, RNA 
expression profiling) to explore whether specific 
genomic  features  correlate  with response  or resistance 
to duvelisib in iNHL.  
Colon  biopsies taken  as standard  of care to 
assess  colitis (if available)  Pharmacodynamic  analysis, immune  cell and  immune 
cell function, protein and genomics analyses  
Abbrevia  tions:  ctDNA:  circulating  tumor  deoxyribonucleic  acid; iNHL:  indolent  non-Hodgkin  lymphoma;  PI3K: 
phosphoinositide  3-kinase;  PTEN:  phosphatase  and tensin homolog;  RNA:  ribonucleic  acid 
In addition,  C-reactive  protein levels  in blood (a  clinical  safety laboratory assessment)  will be 
evaluated as a potential  biomarker and  will be assessed at  Screening  and whenever Grade ≥  2 
diarrhea or any colitis occurs.  
8.9. Medical  Resource  Utilization  and Health  Economics  
Health Economics/Medical  Resource  Utilization and Health Economics parameters are not 
evaluated in this study.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  49 of 80  
 9. STATISTICAL  METHODOLOGY  
A detailed description  of the statistical  methodology for  this study can be  found  in the Statistical 
Analysis Plan (SAP). Deviations from the statistical analyses outlined in this protocol will be 
indicated in the SAP; any further modifications will be noted in the final clinical study  report.  
9.1. Statistical  Hypotheses  
This study will test  the null  hypothesis  that the ORR  for each arm is  ≤ 30% against  the 
alternative that ORR is ≥ 55%.  
9.2. Sample  Size Determination  
The sample  size for each arm was calculated  using  a 2-stage  approach.  
For each  arm:  in the first  stage, [ADDRESS_517926] been followed for a minimum  of 3 cycles  
(18 weeks).  
If there are fewer  than 6 responders (PR  or CR) among  the first  15 subjects, consideration  may 
be given to terminating  the treatment  arm. The decision to proceed  to Stage 2 will be based on  
the totality of data observed, including  types of  responses, safety data, and discontinuation rates. 
The treatment  arm may also not  proceed  to the second  stage if  the totality of  the data is viewed 
as compelling;  such scenarios could include (but  are not  limited to) accumulating  enough data  in 
Stage 1 to conclude  the ORR  exceeds  30%.  If the  treatment  arm proceeds  to the  second stage,  up 
to 36 additional  subjects  will be enrolled for  a total  of 51.  If fewer  than 22 (43%)  responders  (PR 
or CR) are observed in 51 subjects, consideration may  be given to concluding  that the treatment 
schedule does not warrant further study  in this population. The final evaluation  of each schedule 
will be based on the totality of data observed, including  types of responses, safety  data, and  
discontinuation  rates. This design yields 90%  power  under  the assumptions described above;  the 
alpha level (type I error rate) for the study will be controlled at 0.025.  
Subjects  will be stratified by [CONTACT_410580][INVESTIGATOR_014]  (1 or  > 1), bulky disease status  (longest 
diameter of  baseline lesion  < 5 cm or ≥ 5 cm) and time since last recurrence (≥  24 months or  
< 24 months).  
9.3. Populations  for Analyses  
The modified  intent -to-treat (mITT)  analysis set  will include  all subjects who  receive  at least 
[ADDRESS_517927] important endpoints, including  
primary  and secondary  endpoints.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  50 of 80  
 9.4.1. General  Considerations  
Each treatment  arm will  be evaluated separately;  no formal  comparisons  between  treatment  arms 
are planned. Hypothesis testing  will be used for the primary  efficacy  endpoint of ORR for each 
treatment arm. No formal hypothesis testing  will be used for any other endpoints or other study 
data, such as demographics and safety data.  
Tabulations will be produced for appropriate disposition, demographic, baseline,  efficacy, and 
safety parameters. For categorical  variables, summary  tabulations of the number and  percentage 
of subjects within each category  (with a category for missing  data) of the parameter will be  
presented,  as well  as 2-sided  95% CIs, unless  stated  otherwise.  For continuous variables,  the 
number of subjects, mean, median, standard  deviation,  minimum, and maximum  values will be 
presented. Time -to-event  data will  be summarized using  Kaplan -Meier  (KM)  methodology using 
25th, 50th (median),  and 75th  percentiles with associated 2 -sided 95% CIs, as well as number  
and percentage  of censored  observations.  
The Investigator’s assessments of  disease response  will be used as the basis for  the evaluation  of 
the primary and secondary efficacy endpoints.  
[IP_ADDRESS].  Procedures  for Handling  Missing,  Unused,  and Spurious  Data  
All available efficacy  and safety data will  be included  in data listings  and tabulations. In general, 
missing  data will be treated as missing  and no data imputation will be applied, unless otherwise 
specified. Data that  are potentially spurious or  erroneous will  be examined according  to standard 
data management operating procedures. Details of procedures for handling missing, unused or  
spurious  data can be found  in the SAP.  
9.4.2. Primary  Endpoint  Efficacy  Analysis  
The ORR  (proportion  of subjects  achieving  a CR  or PR) will be estimated,  along  with the 
2-sided 95% exact CI. Responses  for the primary ORR analysis will be assessed  using  the 2007 
revised IWG  criteria (Cheson 2007 ). Missing  data will  be imputed by [CONTACT_410602] a response (CR or PR) are non -responders.  
9.4.3. Secondary  Efficacy  Endpoints  Analyses  
• ORR  according  to 2014  Lugano  criteria  (Cheson  2014 ) 
Note:  all additional  secondary response endpoints  will be assessed  separately using 2007 
revised IWG criteria ( Cheson 2007 ) and 2014 Lugano  criteria ( Cheson 2014 ) 
• ORR, at 6, 12, 18, and [ADDRESS_517928] dose of  study  intervention, defined as  the 
proportion of subjects achieving  CR or PR at each of these time points.  
• PFS will be assessed using  KM methods  from  time of first  dose of  study intervention 
to PD or death.  
• TTF will  be calculated as  the time from  first dose of study  intervention until 
discontinuation for any reason and will be summarized using KM methods.  
• DOR  will be calculated for  those  subjects  with a  CR or PR from  the time of first 
response to PD using KM methods.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  51 of 80  
 • OS will be assessed using  KM methods from  time of first  dose of study intervention 
to death.  
• LNRR  will be calculated  as the proportion  of subjects  achieving  ≥ 50% decrease  in 
the sum of the product  of the diameters  (SPD)  of target  lymph  nodes.  
• TTFR will  be calculated for  those  subjects  with a  CR or PR from  the time of first 
dose of study intervention  to time of first CR or PR.  
9.4.4. Secondary  Safety  Endpoints  Analyses  
• Safety analyses will  be performed  on the mITT  population,  and safety  endpoints will 
be tabulated and presented.  
• AEs will be  coded using  the Medical  Dictionary for  Regulatory  Activities  (MedDRA) 
for purposes of summarization.  All AEs occurring during the  study  will be  included 
in by -subject data listings and tabulated by [CONTACT_410603], and  in selected cases, High Level  Group Term and  High Level  Terms. 
AEs will be summarized overall, by [CONTACT_410604].  Events leading  to 
death, SAEs, and events resulting  in treatment discontinuation will be listed and, if 
warranted by [CONTACT_26739], tabulated.  
• AEs of special  interest  (AESI)  will be defined for  analysis  purposes  in the SAP  and 
will be summarized using  the methods as described in the above bullet.  
• Exposure to duvelisib, including  the proportion  of expected  doses received, will  be 
tabulated.  
• Changes from baseline  over time for vital  sign measurements (including  diastolic and 
systolic blood pressure) will be summarized.  By-subject listings of vital sign  
measurements  will be  prepared.  
• Individual subject laboratory parameter values and summary statistics over time will 
be prepared using  descriptive  statistics. Severity of  select  clinical  laboratory measures 
will be determined using  NCI CTCAE  criteria and Grade 3 or  4 laboratory values  will 
be presented in a separate table and listing.  
• The use of concomitant  medications, coded using  World Health Organization Drug 
Dictionary, will be tabulated and included in a by -subject listing.  
• Additional  safety analyses  may be performed to more clearly enumerate rates  of 
toxicities and to further define the safety profile of duvelisib.  
9.4.5. Secondary  PK Endpoints  Analyses  
• PK analyses will  be conducted  on the mITT  population.  
• Blood samples will  be taken for  the analyses of  duvelisib and  metabolite IPI -656 in 
plasma at  the time points  defined in the SoA  (Table 2 ). The relevant  PK parameters 
will be determined using  bioanalytical  data.  The PK data will  be summarized using 
descriptive statistics and will be listed and summarized  in tabular and/or graphical 
form.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  52 of 80  
 • A separate  PK analysis  plan may be developed.  
9.4.6. Exploratory  QoL  Endpoints  Analyses  
• Changes from baseline  over time for ECOG performance status will  be summarized. 
A by -subject listing of ECOG performance status data  will be prepared.  
• Changes from baseline  over time for EQ -5D-3L scores  will be summarized. 
By-subject listings of EQ -5D-3L will be prepared.  
9.4.7. Exploratory  Pharmacodynamic  and Biomarker  Endpoints  Analyses  
• Pharmacodynamic  analyses  will be conducted  on the mITT  population.  
• Prognostic markers such as genetic variation, ctDNA,  immunophenotype,  functional 
immune assays, gene expression, and  circulating  protein, will  be evaluated  relative to 
baseline levels and change to baseline levels.  
• Additional  exploratory  analyses  identified  by [CONTACT_410605].  
• Listing of individual  subject  and summary statistics  for duvelisib effects  on 
biomarkers and graphs of changes versus time will be prepared.  
• Biomarker  effects will  be summarized using  descriptive statistics and associations 
with clinical efficacy and/or safety outcomes  may be explored.  
9.5. Interim  Analyses  
There is no formal interim analysis. Study data for each arm will be evaluated  at the end of 
Stage 1 to  determine whether  a study  arm should  be terminated  or continued  to Stage 2.  Please 
see additional details of the 2 -stage design in Section 9.2. 
9.6. Data  Monitoring  Committee  (DMC)  
This study  will not use a DMC.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  53 of 80  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL 
CONSIDERATIONS:  APPENDICES  
 
Table  11: Appendices  
 
Appendix  Title  Section  
1 Overview  of Disease  Response  Criteria  10.1 
2 CYP3A  Inhibitors,  Inducers,  and Substrates  10.2 
3 Clinical  Laboratory  Tests  10.3 
4 Contraceptive  Guidance  10.4 
5 ECOG  Performance  Status  10.5 
6 Regulatory,  Ethical,  and Study  Oversight  Considerations  10.6 
7 Abbreviations  10.7 
8 Protocol  Summary  of Changes  and Version  History  10.8 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  54 of 80  
 10.1. Appendix  1: Overview  of Disease  Response  Criteria  
10.1.1.  2007  Revised  IWG  Criteria  
Table  12: Revised  Response  Criteria  for Malignant  Lymphoma  (Cheson  2007 ) 
 
Response  Definition  Nodal  Masses  Spleen,  Liver  Bone  Marrow  
CR Disappearance  of 
all evidence  of 
disea  se ( a ) FDG -avid or PET positive 
prior  to therapy;  mass of any 
size permitted  if PET negative  
( b ) Va ria bly FDG -avid or PET 
negative;  regression  to normal 
size on CT  Not palpable, 
nodules  disappeared  Infiltrate  cleared  on 
repeat biopsy; if 
indeterminate  by 
[CONTACT_5293],  
immunohistochemistry 
should be  negative  
PR Regression  of 
measurable 
disease  and no 
new sites ≥ 50% decrease  in SPD of up 
to [ADDRESS_517929]  dominant  masses; 
no increase in size of other 
nodes  
( a ) FDG -avid or PET positive 
prior  to therapy;  1 or more 
PET positive at previously 
involved  site 
( b ) Va ria bly FDG -avid or PET 
negative; regression  on CT  ≥ 50% decrease in 
SPD of nodules  (for 
single nodule in 
greatest  transverse 
dia meter);  no 
increase in size of 
liver or spleen  Irreleva  nt if positive 
prior  to therapy;  cell 
type should be 
specified  
SD Fa ilure to attain 
CR/PR  or PD ( a ) FDG -avid or PET positive 
prior  to therapy;  PET positive 
at prior  sites of disease  and no 
new sites on CT or PET  
( b ) Va ria bly FDG -avid or PET 
negative;  no change  in size of 
previous  lesions  on CT    
Relapsed 
disease  or 
PD Any new lesion 
or increase by  
≥ 50%  of 
previously 
involved  sites 
from  nadir  Appea  rance  of a new lesion(s)  
> 1.5 cm in any axis,  ≥ 50% 
increase  in SPD of more  than 
1 node,  or ≥ 50% increase  in 
longest diameter  of a 
previously identified  node  
> 1 cm in short  axis 
Lesions  PET positive  if FDG - 
avid lymphoma  or PET 
positive prior  to therapy  > 50% increase 
from nadir  in the 
SPD of any previous 
lesions  New  or recurrent 
involvement  
Abbrevia  tions:  CR: complete  remission;  CT: computed  tomography;  FDG:  [18F] fluorodeoxyglucose;  PD: 
progressive  disease;  PET:  positron  emission  tomography;  PR: partial  remission;  SD: stable  disease;  SPD:  sum of the 
product  of the  diameters.  
10.1.2.  [ADDRESS_517930] images  will be assessed  using  the 5 -point  scale  (5PS)  (Table  13), a semi -quantitative  
analysis that  is a pragmatic yet  robust  predictor  of subject  outcome,  then disease response  will be 
assessed using the Lugano response criteria (Table 14 ). 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  55 of 80  
 Table 13:  5-Point  Scale for Positron  Emission Tomography Assessment  (Barrington  
2014 ) 
 
Score  Criterion  
1 No uptake  above  background  
2 Uptake  ≤ mediastinum  
3 Uptake  > mediastinum,  but ≤ liver 
4 Uptake  moderately  > liver*  
5 Uptake  markedly  higher  than liver and/or  new lesions*  
X (New)  areas  of uptake  unlikely  to be related  to lymphoma  
*It is suggested  according  to published  data that score 4  be applied  to uptake greater  than the maximum  standardized 
uptake  value  (SUV)  in a large  region  of normal  liver and score  5 to uptake  2× to 3× greater  than the maximum  SUV 
in the liver.  
Table  14:   Lugano  Response  Criteria  for Malignant  Lymphoma  (Cheson  2014 ) 
 
Response  and Site PET -CT-based  Response  CT-based  Response  
Complete  Response  Complete  metabolic  response  Complete  radiologic  response  
(requires  all of the following)  
Lymph  nodes  and extralymphatic 
sites Score  of 1, 2, or 3* with or without 
a residual  masson 5PS  (Table 13 ) 
It is recognized  that in Waldeyer’s 
ring or extranodal  sites with high 
physiologic uptake or  with 
activation  within  spleen  or marrow 
(e.g., with chemotherapy or  
myeloid  colony -stimulating  
factors),  uptake  may be greater  than 
normal  mediastinum  and/or  liver.  In 
this circumstance,  complete  
metabolic  response  may be inferred 
if uptake  at sites of initia  l 
involvement is  no greater  than 
surrounding  normal  tissue even  if 
the tissue has  high physiologic  
uptake  Target  nodes/nodal  masses  must 
regress  to ≤ 1.5 cm in LDi 
No extralymphatic  sites of disease  
Non-measured  lesions  Not applicable  Absent  
Organ  enlargement  Not applicable  Regress  to normal  
New lesions  None  None  
Bone  marrow  No evidence  of FDG -avid disease  
in bone  marrow  Normal  by [CONTACT_5293];  if 
indeterminate,  IHC negative  
Partial  Response  Partial  metabolic  response  Partial  remission  
(all of the following)  
Lymph  nodes  and extralymphatic  
sites 5PS score  4 or 5 with reduced  
uptake  compared  with baseline  and 
residua  l mass(es)  of any  size 
During treatment,  these findings 
suggest  responding  disease  
At EoT,  these  findings  indicate  
residua  l disease  ≥ 50% decrease  in SPD of up to [ADDRESS_517931], assign  5 mm × 
5 mm as the default value  
When  no longer  visible,  0 × [ADDRESS_517932]-based  Response  
  For a node  × 5 mm ×  5 mm, but 
sma ller than normal,  use actual 
measurement  for calculation  
Non-measured  lesions  Not applicable  Absent/normal,  regressed,  but no 
increase  
Organ  enlargement  Not applicable  Spleen  must  have regressed  by 
≥ 50% in length  beyond  normal  
New lesions  None  None  
Bone  marrow  Residual  uptake  higher  than uptake 
in normal  marrow  but reduced  
compared  with baseline  (diffuse 
uptake  compatible  with reactive 
changes  from  chemotherapy  
allowed).  If there are persistent 
focal  changesin  the marrow  in the 
context of  a nodal  response, 
consideration  should be given to 
further  evaluation  with MRI  or 
biopsy  or an interval  scan Not applicable  
Stable  disease  (no response)  No metabolic  response  Stable  disease  
Target  nodes/nodal  masses,  
extranodal  lesions  5PS score  4 or 5 with no significant  
change  in FDG  uptake  from 
baseline  at interim  or end of 
treatment  < 50% decrease  from  baseline  in 
SPD of up to 6 dominant,  
measurable  nodes  a nd extranodal 
sites; no criteria for  
progressive  disease  are met 
Non-measured  lesions  Not applicable  No increase  consistent  with 
progression  
Organ  enlargement  Not applicable  No increase  consistent  with 
progression  
New lesions  None  None  
Bone  marrow  No change  from  baseline  Not applicable  
Progressive Disease  Progressive  metabolic  disease  Progressive  disease  requires  at 
least  1 of the following:  
Individual  target  nodes/nodal 
ma sses 5PS score  4 or 5 with an increase  in 
intensity of uptake from baseline  
and/or  [COMPANY_003] progression  
Extranodal  lesions  New FDG -a vid foci consistent  with 
lymphoma at interim or  EoT 
a ssessment  An individual  node/lesion  must  be 
abnormal  with:  
LDi > 1.5 cm and 
Increase  by ≥ 50% from  [COMPANY_003] nadir  
and 
An increase  in LDi or SDi from 
nadir  
0.5 cm for lesions  ≤ 2 cm 
1.0 cm for lesions  > [ADDRESS_517933]  increase  by 
> 50% of the extent of  its prior 
increase beyond  baseline (e.g.,  a 
15-cm spleen  must increase to  > 
16 cm). If no prior  splenomegaly,  
must  increase  by [CONTACT_2669] [ADDRESS_517934]-based  Response  
Non-measured  lesions  None  New or clear  progression of 
pre-existing  non-measured  lesions  
New lesions  New FDG -a vid foci consistent  with 
lymphoma rather  than another  
etiology (e.g., infection, 
infla mmation).  If uncertain  
regarding  etiology  of new lesions, 
biopsy or  interval  scan may  be 
considered  Regrowth  of previously  resolved 
lesions  
A new node  > 1.5 cm in  any axis 
A new extranodal  site > 1.0 cm in 
any axis;  if < 1.[ADDRESS_517935]  be a ttributable  to lymphoma 
Assessa  ble disease  of any  size 
unequivocally attributable  to 
lymphoma  
Bone  marrow  New  or recurrent  FDG -avid foci New or  recurrent  involvement  
Abbreviations:  5PS:  5-point  scale;  CT: computed  tomography;  EoT:  endof  treatment;  FDG:  fluorodeoxyglucose; 
IHC:  immunohistochemistry;  LDi: longest  transverse  diameter  of a lesion;  MRI:  magnetic  resonance  imaging;  PET: 
positron  emission  tomography;  [COMPANY_003]:  cross  product  of the LDi and perpendicular  diameter;  SDi: shortest  axis 
perpendicular  to the LDi;  SPD:  sum of the product  of the perpendicular  diameters  for multiple  lesions.  
*A score  of [ADDRESS_517936]  treatment,  especially  if at the time of an 
interim  scan.  However,  in studies  involving  PET where  de-escalation  is investigated,  it may  be preferable  to 
consider  a score  of 3 as inadequate  response  (to avoid  undertreatment).  Measured  dominant  lesions:  Up to [ADDRESS_517937]  dominant  nodes,  nodal  masses,  and extranodal  lesions  selected  to be clearly  measurable  in 2 diameters.  
Nodes  should  preferably  be from  disparate  regions  of the body  and should  include,  where  applicable,  mediastinal  
and retroperitoneal  areas.  Non-nodal  lesions  include  those  in solid  organs  (e.g.,  liver, spleen,  kidneys,  lungs), 
gastrointestinal  (GI) involvement,  cutaneous  lesions,  or those  noted  on palpation.  Non-measured  lesions:  Any 
disease  not selected  as measured,  dominant  disease  and truly assessable  disease  should  be considered  not measured. 
These  sites include  any nodes,  nodal  masses,  and extranodal  sites not selected  as dominant  or measurable  or that do 
not meet  the requirements  for measurability  but are still considered  abnormal,  as well as truly  assessable  disease, 
which  is any site of suspected  disease  that would  be difficult  to follow  quantitatively  with measurement,  including 
pleural  effusions,  ascites,  bone  lesions,  leptomeningeal  disease,  abdominal  masses,  and other  lesions  that cannot  be 
confirmed  and followed  by [CONTACT_9661].  In Waldeyer’s  ring or in extra  nodal  sites (e.g.,  GI tra ct, liver,  bone  marrow), 
FDG  uptake  may be greater  than in the mediastinum with  complete  metabolic  response  but should  be no higher  than 
surrounding  normal  physiologic  uptake  (e.g.,  with marrow  activation  as a result  of chemotherapy  or myeloid  growth 
factors).  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  58 of 80  
 10.2. Appendix  2: CYP3A  Inhibitors,  Inducers,  and Substrates  
10.2.1.  Medications  or Foods  Known  to Inhibit  CYP3A  
The following  list provides medications or foods  known  to induce  or inhibit  CYP3A activity. 
Note that this is not a comprehensive  list of all medications or foods which  may modulate 
CYP3A activity. Additional information can be found at:  
https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionsl  
abeling/ucm093664.htm  
Note:  Subjects receiving duvelisib  are prohibited from  concomitant  use of  medications  or 
foods that are known  to be strong inhibitors or inducers of CYP3A.  
 
Table  15: Classification  of In Vivo  Inhibitors  of CYP3A  
 
Strong  Inhibitors1 Moderate  inhibitors2 Weak  inhibitors3 
Boceprevir,  
cla rithromycin,  conivaptan, 
grapefruit  juice4, indinavir, 
itraconazole,  ketoconazole,  
lopi[INVESTIGATOR_410559]/ritonavir, 
mibefradil5 
nefazodone,  nelfinavir, 
posaconazole,  ritonavir, 
saquinavir,  
tela previr, 
telithromycin,  
voriconazole  Amprenavir,  aprepi[INVESTIGATOR_053], 
atazanavir,  ciprofloxacin,  
darunavir/ritonavir,  diltia  zem, 
erythromycin,  fluconazole,  
fosamprenavir,  gra pefruit  juice4, 
ima tinib,  verapamil  Alpra  zolam,  amiodarone, 
amlodipi[INVESTIGATOR_050],  atorvastatin,  
bica lutamide,  cilostazol,  cimetidine, 
cyclosporine,  fluoxetine, 
fluvoxamine,  ginkgo6, goldenseal6, 
isonia  zid, nilotinib,  
oral contraceptives,  ranitidine, 
ranolazine,  
tipra navir/ritonavir,  zileuton  
1. A strong  inhibitor  for a specific  CYP  is defined  as an inhibitor  that increases  the AUC  of a substrate  for that 
CYP  by ≥ 5 -fold, or results  in a > 80%  decrease  in CL.  
2. A moderate  inhibitor  for a specific  CYP  is defined  as an inhibitor  that increases  the AUC  of a sensitive 
substrate  for that CYP  by < 5-fold but ≥2-fold or results  in a 50-80% decrease  in CL. 
3. A weak  inhibitor  for a specific  CYP  is defined  as an inhibitor  that increases  the AUC  of a sensitive  substrate  for 
that CYP  by < 2-fold but ≥1.25 -fold or results  in a 20-50% decrease  in CL. 
4. The effect  of grapefruit  juice  varies  widely  among  brands  and is concentration -, dose-, and preparation - 
dependent.  Studies  have  shown  that it can be classified  as a “strong  CYP3A  inhibitor”  when  a certain 
prepa  ration  was used (e.g.,  high dose,  double  strength)  or as a “moderate  CYP3A  inhibitor”  when  another 
prepa  ration  was used (e.g.,  low dose,  single  strength).  
5. Withdrawn  from  the United  States  market  because  of safety  reasons.  
6. Herbal  product.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  59 of 80  
 10.2.2.  Medications  Known  to Induce  CYP3A  
Table  16: Classification  of In Vivo  Inducers  of CYP3A  
 
Strong  Inducers  ≥ 80%  decrease 
in AUC  Moderate  Inducers  
50-80%  decrease  in AUC  Weak  Inducers  
20-50%  decrease  in AUC  
Avasimibe1, carbamazepi[INVESTIGATOR_050], 
phenytoin,  rifampin,  St. John’s 
Wort2,3 Bosentan,  efavirenz,  etravirine, 
modafinil,  nafcillin  Amprenavir,  aprepi[INVESTIGATOR_053], 
armodafinil,  Echinacea3 
pi[INVESTIGATOR_051],  prednisone, 
rufina  mide  
Abbrevia  tions:  AUC:  area under  the curve;  CYP3A:  cytochrome P450  3A. 
1. Not a marketed  drug.  
2. The effect  of St. John’s  Wort  varies  widely and  is preparation -dependent.  
3. Herbal  product.  
10.2.3.  Medications  Known  to Be CYP3A  Substrates  
Known sensitive CYP3A substrates and CYP3A substrates with a narrow therapeutic range are 
listed in Table  17. Drugs  or foods  that are substrates  of CYP3A  should only be  used if medically 
necessary and therapeutic alternatives do not exist.  
Additional  information  can be found  at: 
• https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/drugi  
nteractionslabeling/ucm093664.htm  
Table  17: Cytochrome  P450  3A (CYP3A) Substrates  
 
Sensitive  CYP3A  Substrates  
budesonide  mida  zolam  
buspi[INVESTIGATOR_410560]  n simva  statin  
felodipi[INVESTIGATOR_410561]3A  Substrates  with a Narrow  Therapeutic  Range  
a lfentanil  fentanyl  
astemizole  pi[INVESTIGATOR_410562]-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  60 of 80  
 10.3. Appendix  3: Clinical  Laboratory  Tests  
• The tests  detailed in Table 18  will be performed  by [CONTACT_12357].  The timing 
and frequency are detailed in SoA Table 1 . 
• Protocol -specific  requirements for  inclusion or  exclusion of  subjects are detailed in 
Section 5. 
• Additional  tests may be performed  at any time during  the study as determined 
necessary by [CONTACT_9332].  
• Investigators  must  document  their review  of each laboratory  safety  report.  
• The results  of each test must  be entered  in the CRF.  
Table  18: Protocol -required  Safety  Laboratory  Assessments  
 
Laboratory 
Assessments  Parameters  
Hematology  Platelet  Count  RBC  Indices:  
Mean  corpuscular 
volume  (MCV)  White blood cell 
(WBC)  count  with 
Differential:  Red blood  cell (RBC)  Count  
Hemoglobin   Mean corpuscular 
hemoglobin  (MCH)  Neutrophils  
Lymphocytes  Hematocrit  
  % Reticulocytes  Monocytes  
   Eosinophils  
   Basophils  
Clinical 
Chemistry1 Blood  urea 
nitrogen 
(BUN)  Potassium  Aspartate 
Aminotransferase 
(AST)/ Serum  
Glutamic -Oxaloacetic  
Transaminase  (SGOT)  Total  and direct 
bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase  Total  Protein  
   (ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase  (SGPT)   
 Glucose  (non- 
fasting)  Calcium  Alkaline  phosphatase 
(ALP)  Lactate 
dehydrogenase 
(LDH) 
Quantitative  
serum  
immunoglobulins 
(Ig) IgA, IgG, IgM 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  61 of 80  
  
Laboratory 
Assessments  Parameters  
Routine  Urinalysis  • Specific  gravity  
• pH, glucose, protein, blood, ketones, bilirubin,  urobilinogen,  nitrite, 
leukocyte esterase by [CONTACT_5230]  
• Microscopic  examination  (if dipstick  is abnormal)  
Pregnancy  • Highly  sensitive  serum human  chorionic  gonadotropin  (hCG) pregnancy  test 
(as needed for women of childbearing potential)2 
Other  Screening 
Tests  • Viral screening: serology (hepatitis B surface antigen [HBsAg], hepatitis B 
core antibody [HBcAb], hepatitis  C virus  antibody [HVC  Ab], Epstein -Barr 
virus [EBV] antibody, human immunodeficiency virus [HIV] antibody); 
cytomegalovirus  (CMV) via  serology or viral load detection via  polymerase 
chain reaction (PCR). Subjects  with a  negative  HBsAg and positive  HBcAb 
require an undetectable/negative hepatitis  B DNA test (e.g., PCR  test) to be 
enrolled.  
o HIV testing is required for subjects  without documentation of a prior 
negative test result from within the last 9 months. Results will be 
analyzed  locally  and will not be captured  in the study  database. Only 
subjects with negative results will be eligible to enroll.  
• Coagulation  tests:  prothrombin  time (PT), partial  thromboplastin  time (PTT) 
and international normalized ratio (INR)  
• C-reactive  protein  
• Endocrine  function tests: Free  thyroxine  (T4) and thyroid -stimulating 
hormone  (TSH)  
• Human  leukocyte  antigen  (HLA)  typi[INVESTIGATOR_007]:  types  A, B, C,  DRB1, and  DQB1  
NOTES:  
1. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments  
after liver stoppi[INVESTIGATOR_410563]  5. All liver-related  SAEs  must  be 
reported as described in Section 8.3.[ADDRESS_517938].  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  62 of 80  
 10.4. Appendix  4: Contraception  Guidance  
The effects of duvelisib on conception, pregnancy, and  lactation are unknown.  Every woman of 
childbearing  potential  (WCBP)  and male subjects  with a partner  who is a WCBP must  use highly 
effective  methods of contraception as described  below in Section 10.4.1 . A woman  is considered 
to be a  WCBP following  menarche  and until becoming  postmenopausal (i.e., >  [ADDRESS_517939] 1 year),  unless  permanently  sterile.  
At Screening, all  male and female subjects  of reproductive potential  (i.e., not  surgically sterile or 
female subjects who  are not postmenopausal) must agree to use highly effective  methods of  
contraception  for the duration  of the study  intervention,  and for at least [ADDRESS_517940]  or the male partner  (of the 
female subject)  has a documented  history  of a vasectomy  or if the female  subject  or the female  
partner  (of the male subject)  has a documented  history of  bilateral  oophorectomy, hysterectomy, 
or tubal  ligation, or if she is > [ADDRESS_517941] 1 year.  
Section  8.3.9  for requirements  for pregnancy  reporting.  
10.4.1.  Highly Effective  Methods  of Contraception  
Methods  that can achieve a failure rate of less  than 1% per year when used  consistently and 
correctly are considered as highly effective birth control methods.  Such methods include:  
• combined (estrogen and  progestogen  containing) hormonal  contraception associated 
with inhibition of ovulation1: 
o oral 
o intravaginal  
o transdermal  
• progestogen -only hormonal  contraception  associated  with inhibition  of ovulation1: 
o oral 
o injectable  
o implantable2 
• intrauterine  device  (IUD)2 
• intrauterine  hormone -releasing  system  (IUS)2 
• bilateral  tubal  occlusion2 
• vasectomized  partner2,3 
• sexual  abstinence4 
1Hormonal  contraception  may be susceptible  to interaction  with the IMP,  which  may reduce  the efficacy  of 
the contraception method.  
2Contraception  methods  that are considered  to have low user dependency  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  63 of 80  
 3Vasectomized  partner  is a highly  effective  birth control  method  provided  that partner  is the sole sexual  
partner  of the  WCBP  study  participant  and that the vasectomized  partner  has received  medical  assessment 
of the surgica  l success.  
4Sexual  abstinence  is considered  a highly  effective  method  only if defined  as refraining  from  heterosexual 
intercourse  during  the entire  period  of risk associated  with the  study  treatments.  The reliability of  sexual  
abstinence  needs  to be evaluated  in relation  to the duration  of the  clinical  study  and the preferred  and usual 
lifestyle of the patient.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  64 of 80  
 10.5. Appendix  5: Eastern  Cooperative  Oncology  Group  (ECOG) 
Performance  Status  
Grade  ECOG  
0 Fully  active,  able to carry  on all pre-disease  performance  without  restriction  
1 Restricted  in physically  strenuous  activity  but ambulatory  and able to carry  out work  of a 
light or sedentary  nature,  e.g., light housework,  office  work  
2 Ambulatory  and capable  of all self-care but unable  to carry  out any work  activities.  Up and 
about more than  50% of waking  hours  
3 Capable  of only limited  self-care, confined  to bed or chair  more  than 50% of waking  hours  
4 Completely  disabled.  Cannot  carry  on a ny self-care. Totally  confined  to bed or chair  
5 Dea d 
Source:  (Oken 1982 ). 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  65 of 80  
 10.6. Appendix  6: Regulatory,  Ethical,  and Study  Oversight 
Considerations  
10.6.1.  Regulatory  and Ethical  Considerations  
• This study  will be conducted  in accordance with  the protocol  and with the following:  
o Consensus ethical principles derived from  international guidelines  including  the 
Declaration of Helsinki and  Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
o Applicable International  Conference on Harmonisation (ICH)  Good  Clinical 
Practice (GCP) Guidelines  
o Applicable  laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., 
advertisements)  must  be submitted to an IRB/IEC  by [CONTACT_209499]/IEC before the study is initiated.  
• Any amendments  to the protocol  will require  IRB/IEC  approval  before  
implementation of  changes made to the study  design, except  for changes necessary  to 
eliminate an immediate hazard to study subjects.  
• The Investigator  will be responsible  for the following:  
o Providing  written summaries  of the status  of the study to the IRB/IEC  annually or 
more frequently in accordance with the requirements, policies,  and procedures 
established by [CONTACT_1201]/IEC  
o Notifying  the IRB/IEC  of SAEs  or other  significant  safety findings  as required by 
[CONTACT_1744]/IEC procedures  
o Providing  oversight of the conduct of the study at the site and adherence to 
requirements  of 21  CFR, ICH  guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable),  and all other applicable  local 
regulations  
10.6.2.  Financial  Disclosure  
Investigators and Sub -Investigators will  provide the Sponsor  with sufficient, accurate  financial 
information as requested  to allow the Sponsor to submit complete and accurate financial  
certification or disclosure  statements to the appropriate regulatory authorities. Investigators are 
responsible for  providing  information  on financial  interests during  the course of  the study  and for 
1 year after completion of the study.  
10.6.3.  Informed  Consent  Process  
• The Investigator  or his/her  representative  will explain the nature of  the study  to the 
subject and answer all questions regarding the study.  
• Subjects must be informed that their participation is voluntary. Subjects will be 
required to sign a statement  of informed consent  that meets  the requirements  of [ADDRESS_517942]  (HIPAA)  requirements  (where applicable), and  the IRB/IEC  or 
study site.  
• Subjects who are detained by [CONTACT_410606].  
• The medical  record  must  include  a statement  that written  informed  consent  was 
obtained before the subject  was enrolled in the study and  the date the written consent 
was obtained. The authorized person  obtaining  the informed consent must also sign 
the ICF.  
• Subjects must  be re -consented  to the most  current  version of  the ICF(s)  during  their 
participation in the study.  
• A copy  of the ICF(s)  must  be provided  to the subject.  
• A subject  who is  rescreened  is not required to sign another  ICF if the rescreening 
occurs within [ADDRESS_517943]  Data  Protection  
• Subjects will be assigned a unique identifier  during  screening. Any  subject  records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject  
names or  any information that  would make  the subject  identifiable will  not be 
transferred.  
• The subject must be informed  that his/her personal study -related data will be used by 
[CONTACT_410607]. The level  of disclosure  must 
also be explained to the subject who  will be required to give consent for their data to 
be used as described in the informed consent.  
• The subject must be informed that his/her medical records may be examined by 
[CONTACT_410608], by [CONTACT_6667]/IEC members,  and by [CONTACT_9326].  
10.6.5.  Dissemination  of Clinical  Study  Data  
The Sponsor will comply with current regulatory requirements for disclosure and  submission of 
study results. The Sponsor’s  policy  on publication  of study results  is described in Section 10.6.9 . 
10.6.6.  Data  Quality Assurance  
• All subject data relating  to the study will be recorded in the electronic CRF  unless 
transmitted to the Sponsor or designee electronically (e.g., laboratory data). The 
Investigator is responsible for verifying  that data entries are accurate and  correct  by 
[CONTACT_113559].  
• The Investigator must  maintain accurate documentation  (source  data) that  supports 
the information entered in the CRF.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  67 of 80  
 • The Investigator  must  permit  study -related monitoring, audits, IRB/IEC  review, and 
regulatory agency inspections and provide direct access to source  data documents.  
• Monitoring  details describing  strategy (e.g., risk -based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk - 
Based Monitoring), methods, responsibilities, and requirements (including  handling 
of noncompliance issues  and monitoring techniques [central,  remote, or on -site 
monitoring])  are provided  in the Monitoring  Plan.  
• The Sponsor  or designee is responsible for  the data management  of this study, 
including quality checking of the data.  
• The Sponsor  assumes accountability for  actions delegated  to other  individuals (e.g., 
CROs).  
• Study monitors  will perform ongoing  source data verification to confirm that  data 
entered into the CRF by [CONTACT_1191],  complete, and 
verifiable from  source  documents; that the safety and  rights of subjects are being 
protected; and that the study is being  conducted  in accordance with the currently 
approved protocol and any  other study  agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Records and documents, including  signed ICFs, pertaining  to the conduct of this 
study must  be retained by [CONTACT_14344] 2 years  after study completion, for  a 
period of 2 years  after a marketing  application is  approved  for duvelisib in the study 
population, until 2 years after shipment and delivery of the drug for investigational 
use is discontinued, or as long  as required by [CONTACT_56819], whichever is longer.  
No records  may be destroyed during  the retention period without  the written approval 
of the Sponsor. No records may be transferred  to another location or party  without 
written notification to the Sponsor.  
10.6.7.  Source  Documents  
• Source documents  provide evidence for  the existence of  the subject  and substantiate 
the integrity  of the data collected. Source documents are filed  at the Investigator’s 
site. 
• Data  reported  on the CRF or entered  in the CRF  that are transcribed  from  source  
documents  must  be consistent  with the  source  documents  or the discrepancies  must  be 
explained. The Investigator may need  to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what  constitutes  source data  can be found in ICH  guidance  for industry 
E6 GCP: Consolidated Guidance.  
10.6.8.  Study  and Site Start  and Closure  
The study start  date is  the date on which the clinical  study will  be open for  recruitment  of 
subjects.  
The first  act of recruitment  is the first site open  and will be the study  start date.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  68 of 80  
 The Sponsor  or designee reserves  the right  to close the study site or  terminate the study at  any 
time for  any reason (e.g., as necessary for  patient  safety)  at the sole discretion  of the Sponsor. 
Study sites will be closed upon study  completion.  A study site is considered  closed  when all 
required documents and study supplies have  been collected and a study -site closure  visit has 
been performed.  
The Investigator  may initiate study -site closure at  any time, provided  there is reasonable  cause 
and sufficient notice  is given in advance of the intended termination.  
Reasons  for the early closure of  a study site by [CONTACT_410609]:  
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or  local  health authorities, the Sponsor's  procedures, or  GCP  guidelines  
• Inadequate  recruitment  of subjects  by [CONTACT_410610]:  
• Determination  of unexpected,  significant,  or unacceptable  risk to subjects,  including:  
− the occurrence of  AEs with character, severity, or  frequency  that are new  in 
comparison to the existing risk profile  
− data derived from other clinical  studies  or toxicological  studies that  negatively 
influence the risk/benefit assessment  
• Failure  to enter  subjects  at an acceptable  rate 
• Plans  to modify,  suspend, or  discontinue  the development  of the study  intervention  
If the study is prematurely terminated  or suspended,  the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any CRO(s)  used in the study  of the 
reason for  termination  or suspension, as specified  by [CONTACT_1214].  The 
Investigator shall promptly inform the subject and should assure appropriate subject therapy  
and/or  follow -up. 
10.6.9.  Publication  Policy  
• The results of this study may be published or presented  at scientific  meetings with 
prior  approval  of the Sponsor.  The Investigator  agrees to submit  all manuscripts or 
abstracts to the Sponsor before submission. This allows the Sponsor to protect  
proprietary  information  and to provide  comments.  
• The Sponsor  will comply with the requirements for  publication  of study results. In 
accordance  with standard  editorial and ethical practice, the Sponsor will generally 
support  publication  of multi -site studies only in their entirety and  not as individual 
site data. In this case, a coordinating  Investigator [INVESTIGATOR_410564].  
• Authorship will  be determined by  [CONTACT_410611].  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  69 of 80  
 10.7. Appendix  7: Abbreviations  
Table  19: List of Abbreviations  and Definitions  
 
Abbreviation  Definition  
AE Adverse  event  
AESI  Adverse  event  of special  interest  
ALP Alkaline  phosphatase  
ALT  Alanine  aminotransferase  
ASCO  American  Society  of Clinical  Oncology  
AST Aspartate  aminotransferase  
BID Twice  daily  
CEC  Central  Ethics  Committee  
CI Confidence  interval  
CxDx  Cycle  x Day x 
CLL Chronic  lymphocytic  leukemia  
CMV  Cytomegalovirus  
CR Complete  response  
CRF Case  report  form 
CRO  Contract  research  organization  
CTCL  Cutaneous  T-cell lymphoma  
CYP3A  Cytochrome  P450 3A 
DI Dose  interruption  
DNA  Deoxyribonucleic  acid 
DOR  Duration  of response  
DRESS  Drug  reaction  with eosinophilia  and systemic  symptoms  
EBV  Epstein -Barr virus  
eCCr  Estimated  creatinine  clearance  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern  Cooperative  Oncology  Group  
ESMO  European  Society  for Medical  Oncology  
FDA  Food  and Drug  Administration  
FDG  18fluoro -2-deoxy -d-glucose  
FFPE  Formalin -fixed  paraffin -embedded  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  70 of 80  
  
Abbreviation  Definition  
FL Follicular  lymphoma  
GCP  Good  Clinical  Practice  
Gi Giga  (1 x 109) or 1 billion  
HBcAb  Hepatitis  B core antibody  
HBV  Hepatitis  B virus  
hCG Human  chorionic  gonadotropin  
HCV  Hepatitis  C virus  
HIV Human  immunodeficiency  virus;  
HLA  Human  leukocyte  antigen  
HSV  Herpes  simplex  virus  
IHC Immunohistochemistry  
iNHL  indolent  non-Hodgkin  lymphoma  
IB Investigator’s  Brochure  
ICF Informed  consent  form 
IEC Independent  Ethics  Committee  
Ig Immunoglobulin  
IWG  International  Working  Group  
IRB Institutional  Review  Board  
KM Kaplan -Meier  
L Liter  
LDH  Lactate  dehydrogenase  
LNRR  Lymph  node  response  rate 
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mg Milligram  
mITT  Modified  intent -to-treat 
MUGA  Multi -gated  acquisition  
NCCN  National  Comprehensive  Cancer  Network  
NCI CTCAE  National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  Events  
NPP Named  Patient  Program  
ORR  Overall  response  rate 
OS Overall  survival  
PCR Polymerase  chain  reaction  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  71 of 80  
  
Abbreviation  Definition  
PD Progressive  disease  
PE Physical  examination  
PET Positron  emission  tomography  
PFS Progression -free survival  
PI3K  Phosphoinositide  3-kinase  
PJP Pneumocystis  jiroveci  pneumonia  
PK Pharmacokinetics  
PR Partial  response  
PTCL  Peripheral  T-cell lymphoma  
PTEN:  Phosphatase  and tensin  homolog  
QD Once  daily  
QTcF  QT interval  corrected  with Fridericia’s  method  
RBC  Red blood  cell 
RNA  Ribonucleic  acid 
RP2D  Recommended  Phase  2 dose 
R/R Relapsed or  refractory  
SAE Serious  adverse  event  
SD Stable  disease  
SGOT  Serum  glutamic -oxaloacetic  transaminase  
SGPT  Serum  pyruvic transaminase  
SJS Stevens  Johnson  syndrome;  
SLL Small  lymphocytic  lymphoma  
SoA Schedule  of Activities  
SPD Sum of the product  of the diameters  
TEAE  Treatment -emergent  adverse  event  
TEN  Toxic  epi[INVESTIGATOR_410565]-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  72 of 80  
  
10.8. Appendix  8: Protocol  Summary  of Changes  and Version  History  
10.8.1.  Protocol  Version  4.0 (Amendment  5), 18 May  2021  
[IP_ADDRESS].  Amendment  Rationale  and Summary  of Changes  
The primary purpose for this amendment  was to remove  the Long -Term and Survival  F/U visits, 
while continuing  to provide the opportunity for  patients  experiencing  long term benefit  to receive 
study drug. Changes were made in the Schedule of Assessments and  in the body text.  
Additionally, the study duration was modified to end  [ADDRESS_517944]  is randomized. 
COVID -19 vaccine information was also added.  
Minor  language  and format  corrections  were  also done  throughout  the document.  
The revised protocol, Version  4.0, dated 18  May 2021  will be submitted by [CONTACT_737](s)  to 
all applicable IRBs, IECs, or CECs, and by [CONTACT_46579], Inc. (or designee) to all applicable 
Regulatory Authorities.  
Table  20: Summary  of Changes  for Version  4.0 
 
Section(s)  Description  of Change  Rationale for  the Change  
Global  Updated  the version  number  and date of 
protocol from  Version 3.2 dated 08  
December  2020  to Version  4.0 dated  18 May 
2021  Administrative  change  
Global  Minor  corrections  to grammar/spelling  Administrative  changes  
Synopsis 
Section  1.3 
Section  4.1 
Section  4.4 
Section  6.8 
Section  7.1 Removed Long -Term and Survival F/U 
visits,  and revised  study end  date to be [ADDRESS_517945] randomized  Removed the Long -Term and 
Survival F/U visits, which 
required  a revision  to the study 
end date 
Table  2 Removed  all PD/Biomarker sampling  after 
Cycle 2  Re-evaluated  need  for additional 
sample collection after Cycle 2  
Section  6.6.5  Added  COVID -19 vaccines  as allowed 
Concomitant Medications  Global  rollout  of COVID -19 
vaccines addressed with this 
addition  
Section  8.4 Section  removed  as part of Long -Term  and 
Survival F/U removal  Harmonizing protocol with prior 
removal of the Long -Term and 
Survival F/U visits  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  73 of 80  
 10.8.2.  Protocol  Version  3.2 (Amendment  4), 08 December  2020  
[IP_ADDRESS].  Amendment  Rationale  and Summary  of Changes  
Secura Bio, Inc. acquired the global  rights  in Oncology for  the Investigational  Medicinal  Product 
(IMP),  duvelisib (also referred to as Copi[INVESTIGATOR_410566]®) from  Verastem.  Updates  were made  in this  
document  in all  sections, as applicable, to reflect  that Secura Bio is now the Sponsor  for this 
study. This is an administrative change that does not affect the planned study.  
In addition, minor  language  and format  corrections  were  also done  throughout  the document.  
The revised protocol, Version 3.2,  dated 08 December 2020  will be submitted by [CONTACT_3786](s)  to all  applicable IRBs,  IECs,  or CECs,  and by [CONTACT_46579],  Inc. to all  applicable 
Regulatory Authorities.  
10.8.3.  Protocol  Version  3.1 (Amendment  3), 25 February  2020  
[IP_ADDRESS].  Amendment  Rationale  and Summary  of Changes  
The primary  purpose  for this amendment  was to make  minor  administrative  changes  to the 
protocol. Specifically, to provide a consistent  and correct  date of  the amendment  throughout  the 
document. In Version  3.0, the date  of the amendment was not correct in some footers and text 
(28 January 2019  instead  of 28 January 2020).  In addition, a minor change to the ECG note in 
the Schedule of Assessments and  Section 8.2.2 was made to indicate that “QTc measurements 
will be as measured by [CONTACT_410596] ” for consistency with the text  of Exclusion Criterion 
#18. 
10.8.4.  Protocol  Version  3.0 (Amendment  2), 28 January  2020  
[IP_ADDRESS].  Amendment  Rationale  
The primary purpose for  this amendment  was to incorporate changes  made in 3 country -specific 
amendments to address requests from Regulatory  Authorities after their review  of Version 1.0.  
The revised protocol, Version  3.0, dated 28  January 2020  will be submitted by [CONTACT_737](s) 
to all applicable IRBs, IECs, or CECs, and by [CONTACT_46579], Inc. to all applicable Regulatory 
Authorities.  
A summary of key  changes that  were made  to protocol  Version 1.0, including  the rationales for 
these changes, is provided in Table 20 . 
Table  21: Summary  of Changes  for Version  3.0 
 
Section(s)  Description  of Change  Rationale for  the Change  
Global  Updated the version number and date of 
protocol from Version 1.0 dated 04 April 
2019  to Version  3.0 dated  28 January  2020  Administrative  change  
Global  Minor  corrections  to grammar/spelling  Administrative  changes  
Synopsis 
Section  3 Specified  the metabolite  of duvelisib  as 
IPI-656 To clarify  that the  only metabolite 
analyzed  in PK data analysis is  PI- 
656 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  74 of 80  
  
Section(s)  Description  of Change  Rationale for  the Change  
Section  8.5 
Section  9.4.5    
Section  1.2 Legend for Figure  #[ADDRESS_517946]  disease response  frequency  to be 
consistent with Table 1 (Schedule of 
Assessments)  Correction  of error  
Section  1.3 Minor corrections/clarifications and 
reorganizations  to Table  1 (Schedule  of 
Assessments)  Correction of errors  (incorrect or 
missing information), addition of 
clarifications, and elimination of 
sub-header rows  
Section  1.[ADDRESS_517947] 
transformation to a more 
aggressive  lymphoma.  
Section  1.3 Added  details  (e.g., “Day  1” and “Window” 
to describe timing of CT assessment  Clarification  
Section  1.3 Merge  cells for  Bone  Marrow  Biopsy  and/or 
Aspi[INVESTIGATOR_410567], as biopsy  
may be required  at any visit during 
the course of the study, including 
LTFU, to confirm CR  
Section  1.3 Added guidance text to indicate that 
additional ECGs and echocardiograms may 
be conducted  at the Investigator’s  discretion 
as clinically indicated  For consistency with body of the 
protocol  (existing  guidance  text in 
Section  8.2.4)  
Section  1.[ADDRESS_517948] dose 
of study drug  
Section  1.3 
Section  5.2 
Section  10.3 Removal of human T -lymphotrophic  virus 
type 1 (HTLV -1) testing at Screening and 
from exclusion criterion #[ADDRESS_517949] cannot be 
done 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  75 of 80  
  
Section(s)  Description  of Change  Rationale for  the Change  
Section  1.3 
Section  8.1.2  
(Section  8.1.3  in 
prior version)  Changed bone marrow biopsy guidance for 
submission of available pathology reports 
from  “most  recent”  to “within  60 days before 
C1D1”  If a patient had bone marrow 
biopsy/aspi[INVESTIGATOR_410568] a  part of 
standard of care; the pathology 
report data within 60 days of 
C1D1  are more  medically  relevant 
than results from an earlier time 
point  
Section  1.3 
Section  8.2.1  Modified  schedule  of assessments  to include 
Full Physical Examination (PE) at C1D1, 
and Focused PE and Vital Signs at every 
visit. Re -ordered  SoA rows  and text sections 
to present full PE, focused PE, and Vital 
Sign assessments  sequentially. Align SoA 
notes and text descriptions.  To increase frequency of vital 
signs measurements and provide 
additional  safety  monitoring. Re - 
ordering and text alignment was 
done for clarity  
Section  1.3 
Section  10.3 Removed  cortisol  testing  at Screening  Not needed  for this clinical  study  
Section  1.3 
Section  10.3 Added  description  of HLA  types included  in 
the HLA assessment at Screening  To provide  additional  assessment 
details for clarity  
Section  2.1 
Section  2.2 
Section  4.2 
Section  11 Added information to Rationale, 
Background, and  Scientific  Rationale 
sections, with supporting references  To provide  justification  for study 
design  and population, as  well as 
additional information on 
indication  and available  therapi[INVESTIGATOR_410569]  5.1 Modified inclusion criterion #4 to indicate 
that subjects are  required  to be candidates  for 
a subsequent line of therapy  To clarify  eligibility  requirements  
Section  5.1 Modified  inclusion  criterion  #[ADDRESS_517950] hemoglobin level  
≥ 8 g/dL To clarify  the eligibility  based  on 
hemoglobin  levels  
Section  5.1 
Section  11 Modified  inclusion  criterion  #5 to  indicate 
that renal function will be measured by 
[CONTACT_410612]  5.1 
Section  5.3 
Section  6.6.4  
Section  8.3.9  
Section  10.4 Modified inclusion criterion #[ADDRESS_517951] be used  To align contraception guidance 
with the Clinical  Trials  Facilitation 
Group (CFTG) guidance  
Section  5.2 Modified exclusion criterion #14 to remove 
requirement for HBV  viral prophylaxis  with 
entecavir (or equivalent) concomitant with  Monitoring for reactivation of 
HBV is a sufficient precaution 
against  active HBV  infection  for 
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  76 of 80  
  
Section(s)  Description  of Change  Rationale for  the Change  
 duvelisib  treatment  for subjects  who have 
positive HBcAB and negative DNA  subjects who have  positive 
HBcAB  and negative  DNA  
Section  5.4 (new)  Moved definition of enrolled from the 
Sample Size Determination section  
(Section  9.2) to  a new section  (Definition  of 
Enrolled)  To improve  clarity  
Section  5.[ADDRESS_517952] number 
as for the initial screening  To align  with current  practice  
Section  6.6.2  
Section  10.7 Added  definition  for the  term “Gi”  as 1 X 
109 (1 billion cells or giga)  To clearly  distinguish  the “Gi” 
abbreviation from the “GI” 
abbreviation  
Section  6.6.[ADDRESS_517953] dose of study drug  To provide additional safety 
protection  for study  subjects  after 
treatment discontinuation  
Section  6.8 Added  the following  statement: “Long -term 
continued treatment will be provided either 
in a separate clinical study or expanded 
access  program consistent with local 
regulations”  To clarify how subjects who are 
still receiving  treatment  at the end 
of the study will access  duvelisib 
after the end of the study  
Section  8 
Section  8.2.1  Deleted text describing timing of Screening 
activities, including  the following  statement: 
“A full PE will be conducted at Screening.”  To align with the protocol 
template  by [CONTACT_410613]  8.1.1  
(Section  8.1.2  in 
prior version)  Modified  text describing  PET-CT To align  with SoA 
Section  8.3.6  Modified Clinical Laboratory Adverse  Event 
section to remove language that restricts the 
constitution  of abnormal laboratory  values  as 
AEs To align  with ICH Guideline 
E.2.A  
Section  8.3.8  Clarified that only cases of overdose that 
cause an SAE are required to be reported 
within 24 hours, and that Investigator will 
determine  if and  when  dosing  should  resume  To clarify  and expand  overdose 
guidance  
Section  5.4 (new, 
statement was 
moved  from 
Section 9.2 in 
prior version)  
Section  10.6.[ADDRESS_517954]’s legal 
representative  To address request by [CONTACT_410614]-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  77 of 80  
  
Section(s)  Description  of Change  Rationale for  the Change  
Section  9.[ADDRESS_517955] and deleted 
“(PET)” from title of Table 13  To align  with nomenclature  in 
published response criteria  
Section  10.2.1  Footnote 3: corrected the definition of a  
weak  CYP inhibitor  based  on FDA  definition  To correct  a textual  error  
Section  10.6.[ADDRESS_517956]  updated  protocol  
Section  10.8.1  Added  Summary  of Changes  made  in 
Version  3.0 Administrative  change  
Section  10.8.2  Updated  version  history  Administrative  change  
10.8.5.  Version  History  
Table  22: Primary  Reason  for Each  Version  
 
Version  Primary  Reason  for Version  
4.0 To revise  study  assessments/sample  collection  and incorporate  COVID -[ADDRESS_517957]  minor  errors  in Version  3.0 
3.0 To incorporate Version  2.0 country -specific  changes  into a global  amendment  
2.0 (3 country -specific 
amendments)  To address  country -specific requests  from Czech  Republic/Italian,  German,  and 
United  Kingdom  regula  tory authorities  after their review  of global  Version  1.0. 
There was no global  Version 2.0.  
1.0 Origina  l version  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  78 of 80  
 11. REFERENCES  
Barrington SF, Mikhaeel  NG, Kostakoglu L, et  al. Role of imaging  in the staging and response 
assessment  of lymphoma:  consensus of the International  Conference on Malignant  Lymphomas 
Imaging Working  Group. Journal  of clinical  oncology  : official  journal  of the American Society 
of Clinical Oncology. 2014;32(27):3048 -3058.  
 
Casulo C, By[CONTACT_147118] M, Dawson KL, et  al. Early Relapse of Follicular  Lymphoma After  Rituximab 
Plus Cyclophosphamide, Doxorubicin,  Vincristine, and  Prednisone  Defines  Patients  at High Risk 
for Death:  An Analysis From the National  LymphoCare  Study. J Clin Oncol. 2015;33(23):2516 - 
2522.  
Cheson BD. Current  approaches to therapy  for indolent  non-Hodgkin's lymphoma.  Oncology 
(Williston Park). 1998;12([ADDRESS_517958] 8):25 -34. 
 
Cheson BD, Pfistner  B, Juweid ME, et  al. Revised response criteria for  malignant  lymphoma. J 
Clin Oncol. 2007;25(5):579 -586. 
 
Cheson BD,  Fisher  RI, Barrington SF, et  al. Recommendations  for initial  evaluation,  staging,  and 
response assessment of Hodgkin  and non -Hodgkin lymphoma: the Lugano classification. J Clin 
Oncol. 2014;32(27):3059 -3068.  
 
Cockcroft  DW,  Gault  MH. Prediction  of creatinine  clearance  from  serum  creatinine.  Nephron.  
1976;16(1):31 -41. 
COPI[INVESTIGATOR_410541].  (duvelisib), capsules for oral  use. US  Prescribing  Information. 2018; 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf . 
Coutre  SE, Barrientos  JC, Brown JR,  et al. Management  of adverse  events  associated with 
idelalisib treatment: expert panel opi[INVESTIGATOR_1649]. Leuk Lymphoma. 2015;56(10):2779 -2786.  
 
Curran E,  Smith SM. Phosphoinositide  3-kinase  inhibitors  in lymphoma.  Current  Opi[INVESTIGATOR_410570]. 2014;26(5):469 -475. 
 
Dong  S, Guinn D, Dubovsky  J, et al. IPI -145 antagonizes  intrinsic  and extrinsic survival  signals 
in chronic lymphocytic leukemia cells. Blood. 2014;124(24):3583 -3586.  
ESMO. ESMO  Clinical Practice Guidelines: Haematological Malignancies. 2019; 
https://oncologypro.esmo.org/Guidelines/Clinical -Practice -Guidelines/Haematological - 
Malignancies , 2019.  
Faia K,  Proctor  J, Andrade  P, et al. High  throughput  in vitro combination  sensitivity screen in 
hematologic malignancies with the phosphoinositide -3 kinase  (PI3K) -delta,gamma Inhibitor, 
duvelisib. Paper presented at: ASCO Annual Meeting; May 31, 2015,  2015; Chicago, IL.  
Protocol  VS-[ADDRESS_517959], et al.  Prognosis  of follicular  lymphoma:  a predictive  model 
based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood.  
2000;95(3):[ADDRESS_517960]  of dose  modifications  on response  to duvelisib  in 
patients with relapsed/refractory  (R/R) CLL/SLL in the DUO trial. J Clin Oncol.  
2019;37(suppl):abstract  7523.  
 
Fruman DA,  Chiu H,  Hopkins  BD, Bagrodia  S, Cantley LC,  Abraham  RT. The PI3K  Pathway in 
Human Disease. Cell. 2017;170(4):605 -635. 
Hitz F,  Ketterer  N, Lohri  A, et al.  Diagnosis  and treatment  of follicular  lymphoma.  Swiss 
medical weekly. 2011;141:w13247.  
NCCN. National  Comprehensive Cancer Network  Clinical  Practice Guidelines in Oncology 
(NCCN Guidelines): Non -Hodgkin's Lymphomas Version 4.2014. [Guidelines]. 2019; 
http://www.nccn.org/about/nhl.pdf , 2019.  
NCI-SEER. National  Cancer  Institute SEER  Program: Cancer  Stat Facts:  Non-Hodgkin 
Lymphoma. 2019; https://seer.cancer.gov/statfacts/html/nhl.html , 2019.  
 
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative  Oncology  Group.  American  journal  of clinical  oncology.  1982;5(6):649 -655. 
 
Ortiz -Maldonado V,  García -Morillo M,  Delgado J.  The biology behind PI3K  inhibition  in 
chronic lymphocytic leukaemia. Therapeutic advances in hematology. 2015;6(1):25 -36. 
Sehn LH, Chua N, Mayer  J, et al. Obinutuzumab  plus bendamustine versus bendamustine 
monotherapy in patients with rituximab -refractory indolent non -Hodgkin lymphoma 
(GADOLIN): a  randomised,  controlled, open -label,  multicentre,  phase  3 trial. The Lancet 
Oncology. 2016;17(8):1081 -1093.  
 
Smith  TJ, Bohlke K,  Lyman GH,  et al. Recommendations  for the Use of  WBC  Growth Factors: 
American Society of Clinical Oncology Clinical Practice Guideline  Update.  Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2015;33(28):3199 - 
3212.  
 
Steele  AJ. PI3K  in CLL:  are 2 isoforms  better  than 1? Blood.  2014;124:3508 -3510.  
Swerdlow  SH, Campo E,  Pi[INVESTIGATOR_27604], et  al. The  2016 revision of  the World Health Organization 
classification of lymphoid neoplasms. Blood. 2016;127(20):2375 -2390.  
Protocol  VS-0145 -229, Version  4.0 
Duvelisib  Secura  Bio, Inc. 
19 May 2021  CONFIDENTIAL  Page  80 of 80  
 Westin JR. Status  of PI3K/Akt/mTOR  Pathway Inhibitors  in Lymphoma.  Clinical  Lymphoma, 
Myeloma and Leukemia. 2014;14(5):335 -342. 